,PageNo,Text
0,page_0,"Protocol Number: v. 3.0 Date: 11 August 2020 1 Title: Detection of Progressive Disease in Metastatic Colorectal Cancer Patients by NPY Methylation in Liquid Biopsies LEAD -IN FOLICOLOR TRIAL Clinical Study Sponsor: Antwerp University Hospital Drie Eikenstraat 655 B-2650 EDEGEM Confidentiality Notice This document contains confidential information. This document must not be disclosed to anyone other than the study staff and members of the independent ethics committee/institutional review board. The information in this document cannot be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Antwerp University Hospital. If you have questions regarding how this document may be used or shared, please send a mail to folicolor @uza.be"
1,page_1,"Protocol Number: v. 3.0 Date: 11 August 2020 2 PROTOCOL SIGNATURE SHEET Detection of Progressive Disease in Metastatic Colorectal Cancer Patients by NPY Methylation in Liquid Biopsies LEAD -IN FOLICOLOR Trial Version: v. 3.0 – Belgium (11 August 2020 ) The undersigned confirm that the following protocol has been agreed and accepted and that the Principal Investigator agrees to conduct the trial in compliance with the approved protocol and will adhere to the principles outlined in the requirements for the conduct of clin ical trials in the EU as provided for in ""Directive 2001/20/EC”, and any subsequent amendments, GCP guidelines, the Belgian law of May 7th 2004 regarding experiments on the human person, the Sponsor’s SOPs, and other regulatory requirements as amended. I a gree to ensure that the confidential information contained in this document will not be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of the Sponsor. Name + function Site Signature Date (DD/MM/YYYY) Principal Investigator Belgium"
2,page_2,"Protocol Number: v. 3.0 Date: 11 August 2020 3 PROTOCOL SYNOPSIS Study title LEAD -IN FOLICOLOR TRIAL: DETECTION OF PROGRESSIVE DISEASE IN METASTATIC COLORECTAL CANCER PATIENTS BY NPY METHYLATION IN LIQUID BIOPSIES Type of study Prospective, multicentric interventional study Sponsor Antwerp University Hospital (UZA) Funding Amgen Indication RAS and BRAF wild-type, unresectable, metastatic colorectal c ancer, first-line treatment FOLFOX/FOLFIRI and panitumumab . Study design Prospective, multicentric interventi onal study to optimize the cutoff value of NPY methylation in liquid biopsies in metastatic colorectal cancer patients treated with first-line FOLFOX/FOLFIRI and panitumumab . Inclusion is possible after histologically or cytologically proven colorectal adenocarcinoma with metastatic lesions according to RECIST 1.1 at the start of first- line treatment using FOLFOX/FOLFIRI and panitumumab . Patient must have a proven RAS and BRAF wild-type tumor . Patients will be followed by study protocol up to and including the first CT scan following the last liquid biops ies taken , or when a follow -up period of 11 months is reached, until death, until metastasectomy, until lost to follow -up or until (consent ) withdrawal.  Study objectives The primary objective of this study is to optimize the cutoff value of NPY methylation in liquid biopsies (ctDNA) in metastatic colorectal cancer patients receiving first-line FOLFOX/ FOLFIRI and panitumumab. The secondary objective is to deter mine the progression free and 9 -month survival of metastatic colorectal cancer patients. Exploratory objectives will include, but will not be limited to the following:  To explore and compare the use of ctDNA and CEA to predict progression ;  Further exploration of ctDNA in liquid"
3,page_3,"Protocol Number: v. 3.0 Date: 11 August 2020 4 biopsies a nd searching for novel biomarkers ;  To assess the quality of life and the patient experience of metastatic colorectal cancer patients with regard to the use of liquid biopsies for follow -up. Included treatment First-line FOLFOX/FOLFIRI and panitumumab. Included dosing regimen and route Chemotherapeutic agents will be given as an intravenous infusion at a dose and interval consistent with standard institutional practice. Study population Metastatic colorectal cancer patients starting first-line FOLFOX/FOLFIRI and panitumumab . Main inclusion criteria Key Inclusion Criteria (see 5.1 for complete list of inclusion criteria):  Man or woman ≥ 18 years of age at the time the informed consent is obtained   ECOG performance status of 0 or 1  Histologically or cytologically confirmed adenocarcinoma of the colon or rectum in subjects with unresectable metastatic (M1) disease  At least 1 uni -dimensionally measurable lesion of at least 10 mm per RECIST 1.1 guidelines using conventional techniques (CT scan). Lesion m ust not be chosen from a previously irradiated field, unless there has been documented disease progression in that field after irradiation and prior to inclusion . All sites of disease must be evaluated  28 days prior to the start of first -line therapy   Wild-type RAS tumor status (of tumor tissue)  Wild-type BRAF tumor status (of tumor tissue)  Adeq uate hematolog ic, renal, hepatic and coagulation function   Starting a first-line treatment with a combination of FOLFOX/FOLFIRI and panitumumab Main exclusion criteria Key Exclusion Criteria (see 5.2 for complete list of exclusion criteria):  History of prior or concurr ent centr al nervous system metastases   History of other malignancy, except: o Malignancy treated with curative intent and with no known active disease present for ≥ 3 years prior to start therapy and felt to be at low risk for recurrence by the treating physician o Adequately treated non-"
4,page_4,"Protocol Number: v. 3.0 Date: 11 August 2020 5 melanomatous skin cancer or lentigo maligna without evidence of disease o Adequately treated cervical carcinoma in situ without evidence of disease o Prostatic intraepithelial neoplasia without evidence of prostate cancer  Prior chemotherapy or other systemic anticancer therapy for the treatment of metastatic colorectal carcinoma including but not limited to bevacizumab and anti - EGFR therapy (e .g. cetuximab, panitumumab, erlotinib, gefitinib, lapatinib)   Prior adjuvant chemotherapy (including oxaliplatin therapy) or other adjuvant systemic anticancer therapy including but not limited to bevacizumab and anti -EGFR therapy (e.g. cetuximab, panitumumab, erlotinib, gefitinib, lapatinib) for the treatment of colorectal cancer ≤ 6 months prior to start therapy with the following exceptions:  o Subjects may have received prior fluoropyrimidine therapy if administered solely for the purpose of radiosensitization for the adjuvant or neoadjuvant treatment of rectal cancer  Radiotherapy ≤ 14 days prior to start therapy . Subjects must have recovered from all radiotherapy -related toxicities.   Significant cardiovascular risk   History of interstitial lung disease (e .g., pneumonitis or pulmonary fibrosis) or evidence of interstitia l lung disease on diagnostic CT scan  Active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as ≥ CTC grade 2, [CTCAE version 5.0])  Peripheral sensory neuropathy (≥ CTC grade 2 [CTCAE version 5.0] Total sample size The calculated sample size is 60 subjects"
5,page_5,"Protocol Number: v. 3.0 Date: 11 August 2020 6 Planned study visits Screening period /eligibility check (M b):  Additional visit for CT scan if diagnostic CT scan is > 28 days before start of first - line therapy  1 EDTA tube to check hematologic, renal, hepatic, metabolic, and coagulation function < 14 days before start of first -line therapy Inclusion  Questionnaire o Quality of Life (EORTC QLQ - C30 & EORTC QLQ -CR29 ) Start first -line therapy ( M0):  Start cycle 1 of first-line therapy (FOLFOX/FOLFIRI and pani tumumab)  Liquid biops y sampling: o LB0 to measure the ctDNA level o LBa and LB b for further research Follow -up:  Biweekly liquid biopsy sampling up to and including 9 months after start first - line therapy  Every 8 weeks : CT scan combined with CEA up to and including the first CT scan following the last liquid biopsies taken  M9: Quality of Life (EORTC QLQ -C30 & EORTC QLQ -CR29) + p atient experience End of Study (EOS) :  Day on which the first CT scan is performed following the last liquid biopsies ta ken, or when 11 months of follow -up is reached. Safety parameters Clinical and laboratory events will be reported according to the National Cancer Institute – Common Terminology Criteria for Adverse Events (NCI-CTCAE v.5.0 ). Efficacy parameters Progression will be assessed using standard imaging ( CT scan ) based on RECIST criteria 1.1. The level of c tDNA will be assessed through NPY methylation. Laboratory parameters and biomarkers ctDNA levels and standard laboratory parameters (hematology, biochemistry, liver function tests, TSH, urinalysis ). Additional laboratory assessments as deemed necessary by the treating physician. CEA every 8 weeks (combined with CT scan and LB) Imaging parameters Computed tomography (CT)"
6,page_6,"Protocol Number: v. 3.0 Date: 11 August 2020 7 Statistics To determine the optimal cut -off value of the NPY methylation to discriminate between progressive and non -progressive disease (as determined by CT), we will develop a Receiver Operating Characteristic (ROC) curve with data of this lead -in study. ROC curves show the trade -off between sensitivity and specificity and the Area Under the Curve (AUC) is considered as an index of accuracy. In order to construct a 95% confidence interval for the AUC of width 0.2 and assuming an AUC of 0.9 we need a least a group o f 27 patients with progressive disease and a group of 27 patients without pro gressive disease. Assuming a median PFS of 9 months, we would need to include 54 patients and follow them up for 9 months. However, it is expected that about 10- 15% of the study p opulation may become resectable by conversion therapy. Taking this into account, the total number of patients to be included is 60."
7,page_7,Protocol Number: v. 3.0 Date: 11 August 2020 8 ABBREVIATION LIST Abbreviation Definition/Explanation UZA Antwerp University Hospital AE Adverse event ALT Alanine aminotransfe rase ANC Absolute neutrophil count aPTT Activated partial thromboplastin time AST Aspartaat -aminotransfe rase cfDNA Cell free DNA CEA Carcinoembryonic antigen CMG Centre of Medical Genetics CNS Central nervous system CNS CR Central nervous system Complete response CRC Colorectal cancer CSR Clinical study report CTC Common terminology criteria CTCAE Common terminology criteria for adverse events ctDNA Circulating tumor DNA ddPCR Digital droplet PCR DICOM Digital Imaging and Communications in Medicine DMC Data monitoring committee DNA Deoxyribonucleic acid ECOG Eastern cooperative oncology group eCRF Electronic case report form EGFR Epidermal growth factor receptor EORTC European Organisation for Research and Treatment of Cancer EOS End of Study GDP Guanosine 5’ -diphosphate GFR Glomerular filtration rate GGT Gamma -glutamyl transfe rase GOT Glutamic -oxaloacetic transaminase GPT Glutamic -pyruvic transaminase GTP Guanosine -5’-triphosphate HCG Human chorionic gonadotropin Hgb Hemoglobin HIV Human immunodeficiency virus ICF Informed consent form
8,page_8,Protocol Number: v. 3.0 Date: 11 August 2020 9 ICH International conference on harmoni zation ID Identification number INR International normalized ratio LB Liquid biopsy LDH Lactate dehydrogenase MAP Mitogen -activated protein kinase mCRC Metastatic colorectal cancer MSI Microsatellite instability NCI-CTCAE National cancer institute – common terminology criteria for adverse events PACS PD Picture Archiving and Communication System Progressive disease PFS PR Progression -free survival Partial response PTT Partial thromboplastin time PTT Partial thromboplastin time QoL Quality of life RAF Rapidly accelerated fibrosarcoma RECIST Response evaluation criteria in solid tumors SAE SD Serious adverse event Stable disease TGF-α Transforming growth factor alpha TMG Trial management group TSH Thyroid stimulating hormone UPC Urine protein creatinine USA United States of America VPN Virtual private network
9,page_9,Protocol Number: v. 3.0 Date: 11 August 2020 10 TABLE OF CONTENTS Protocol Synopsis ................................ ................................ ................................ .................... 3 Abbreviation list ................................ ................................ ................................ ........................ 8 Table of Content s ................................ ................................ ................................ ................... 10 1 Background and rationale ................................ ................................ ............................. 13 Disease and treatment ................................ ................................ ...................... 13 Circulating Tumor DNA ................................ ................................ ..................... 13 Exploration of epigenetic methylation alterations in ctDNA ............................. 14 Rationale ................................ ................................ ................................ ........... 14 2 Objectives ................................ ................................ ................................ ..................... 16 Primary objectiv e ................................ ................................ .............................. 16 Secondary objectives ................................ ................................ ........................ 16 Exploratory objectives ................................ ................................ ....................... 16 3 Study endpoints ................................ ................................ ................................ ............ 17 Primary endpoint ................................ ................................ ............................... 17 Secondary endpoints ................................ ................................ ........................ 17 Explor atory endpoints ................................ ................................ ....................... 17 4 Study population ................................ ................................ ................................ ........... 17 Number of centers ................................ ................................ ............................ 17 5 Subject el igibility ................................ ................................ ................................ ........... 18 Inclusion Criteria ................................ ................................ ............................... 18 Disease related ................................ ................................ ................. 18 Demographic ................................ ................................ .................... 18 Laboratory ................................ ................................ ......................... 18 Exclusion Criteria ................................ ................................ .............................. 20 Disease Related ................................ ................................ ............... 20 Other Medications ................................ ................................ ............ 20 Gene ral ................................ ................................ ............................. 20 6 Study schedule and procedures ................................ ................................ ................... 22 Screening period/ eligibility check ................................ ................................ .... 22 Pre-screening ................................ ................................ ................... 22 Signing of Informed Consent ................................ ............................ 22 Post-screening ................................ ................................ .................. 22 Inclusio n ................................ ................................ ................................ ............ 23 Start first -line therapy ................................ ................................ ........................ 23 Follow -up................................ ................................ ................................ ........... 23 Sample collectio n ................................ ................................ .............................. 25
10,page_10,Protocol Number: v. 3.0 Date: 11 August 2020 11 RAS and BRAF wild-type tumor status ................................ ............ 25 CEA level ................................ ................................ .......................... 25 Liquid biops ies ................................ ................................ .................. 25 Questionnaire ................................ ................................ ................................ .... 26 Protocol compliance ................................ ................................ ......................... 26 End of study ................................ ................................ ................................ ...... 26 Study completion ................................ ................................ .............. 26 Changes in a patient’s condition ................................ ...................... 27 Metastasectomy ................................ ................................ ............... 27 Death ................................ ................................ ................................ 28 Withdrawal of consent ................................ ................................ ...... 28 Withdrawn consent with data withdrawal ................................ ......... 28 Lost to follow -up ................................ ................................ ............... 28 Duration of the study ................................ ................................ ......................... 29 Early study termination ................................ ................................ ..... 29 7 Methodology ................................ ................................ ................................ ................. 30 Study schedule ................................ ................................ ................................ . 30 Assessment s and study visits ................................ ................................ .......... 31 Screening period (Mb) ................................ ................................ ...... 31 Start first -line therapy (M0) ................................ ............................... 32 M0 + every 2 weeks (up to and including M9) ................................ . 32 M0 + every 8 weeks ................................ ................................ ......... 33 End of study [EOS] in case of study completion .............................. 33 End of study in case of metastasectomy ................................ ......... 34 End of study in case of changes in a patient’s condition ................. 34 End of study in case of withdrawal ................................ ................... 34 End of study in case of lost to follow -up ................................ .......... 34 End of study in case of death ................................ ........................... 34 Summary of study procedures ................................ ................................ ......... 35 Summary of study specific procedures ................................ ............ 35 Summary of standard of care study procedures .............................. 35 Data collection and data storage encoding ................................ ...................... 36 Evaluation of data ................................ ................................ ............................. 36 Tumo r response evaluation ................................ .............................. 36 ctDNA analysis ................................ ................................ ................. 36 8 Statistica l considerations ................................ ................................ .............................. 36 Sample size calculation ................................ ................................ .................... 36 Primary analysis ................................ ................................ ................................ 37 Secondar y analysis ................................ ................................ ........................... 37 Exploratory analysis ................................ ................................ .......................... 37 9 Safety reporting ................................ ................................ ................................ ............. 39 Ethical Committee ................................ ................................ ............................. 39
11,page_11,"Protocol Number: v. 3.0 Date: 11 August 2020 12 Adverse events ................................ ................................ ................................ . 39 Definition Adverse Event (AE) ................................ .......................... 39 Definition Unexpected Adverse Event (UAE) ................................ .. 39 Recording of AEs ................................ ................................ .............. 39 Follow -up of adverse events ................................ ............................ 40 Serious Adverse Events ................................ ................................ ................... 40 Definition Serious Adverse Event ................................ .................... 40 Recording of SAEs ................................ ................................ ........... 40 (Suspected) Unexpected (Serious) Adverse Reactions ................................ .. 41 Annual report ................................ ................................ ................................ .... 41 10 Administration procedures and publication ................................ ................................ .. 42 Regulatory Approval ................................ ................................ ......................... 42 Publication Policy ................................ ................................ .............................. 42 Contractual and Financial Details ................................ ................................ ..... 42 Insurance, Indemnity and Compensation ................................ ......................... 42 11 Monitoring ................................ ................................ ................................ ..................... 43 Overview of data collection ................................ ................................ ............... 43 Mandatory data ................................ ................................ ................................ . 44 Data entry & monitoring guidelines ................................ ................................ .. 44 12 Study administration ................................ ................................ ................................ ..... 45 Coordinating Study Team ................................ ................................ ................. 45 13 Conflict of Interest Policy ................................ ................................ .............................. 45 14 References ................................ ................................ ................................ .................... 46 15 Appendix ................................ ................................ ................................ ....................... 49 Follow -Up Scheme ................................ ................................ ........................... 49 Questionnaire 1 (Dutch version) ................................ ................................ ....... 50 Questionnaire 1 (French version) ................................ ................................ ..... 55 Questionnaire 2 (Dutch version) ................................ ................................ ....... 60 Questionnaire 2 (French version) ................................ ................................ ..... 69 RECIST guideline ( version 1.1) ................................ ................................ ........ 78"
12,page_12,"Protocol Number: v. 3.0 Date: 11 August 2020 13 1 BACKGROUND AND RATION ALE Disease and treatment Colorectal cancer (CRC) is the third most common cancer in both men and women and a major cause of cancer related death. In 2018, there were approximately 1.8 million new cases of CRC worldwide and an estimated number of 881 .000 deaths, accounting for 10% of all cancer related deaths. The incidence and mortality of CRC is still ris ing (1). Of newly diagnosed patients, 15% to 25% have metastatic disease at diagnos is and up to 50% of all patients eventually develop metastatic disease (2, 3) . As of 2009, three monoclonal antibodies have regulatory approval in multiple countries for the treatment of colorectal cancer (CRC): cetuximab (Erbitux®) and panitumumab (Vectibix®), both of which are directed against the epidermal growth factor receptor (EGFR), and bevacizumab (Avastin®), which is directed against vascular endothelial growth factor. The development of these three agents has provided additional therapeutic options for patients. However, metastatic colorectal cancer (mCRC) cannot be cured with the currently available chemotherapy regimens, and there is a continued need to improve the current treatment. The EGFR pathway has been shown to play an i mportant role in carcinogenesis, and inhibiting this pathway with anti -EGFR antibodies has been shown to have clinical efficacy in the treatment of metastatic colorectal cancer in subjects whose tumors express wild -type RAS (4-6). Approximately 60% of subjects presenting with mCRC have tumors without activating RAS mutations (6). RAS mutation status may have prognostic significance and is predictive of response to cetuximab and panitumumab therapy in CRC (5-8). The addition of EGFR -targeted therapies to chemotherapy for the first -line treatment of wild-type (WT) RAS metastatic colorectal cancer has improved patient’s objective response rate (ORR), progression -free survival (PFS) and overall survival (OS) (9-12). For this reason, current guidelines recommend their use in combination with the most common backbone chemotherapeutic regimens such as FOLFOX [folinic acid, 5 -fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5 - fluorouracil, and irinotecan] (13). Circulating Tumor DNA In the past five years , liquid biopsies h ave been intensively studied as a new promising technique for the diagnosis and follow -up of CRC. Liquid biopsy is a technique in which non -solid biological tissues such as urine, stool or peripheral blood are sampled and analyzed (14). They are, for example, used for the detection of abnormally e xpressed biological markers manifested during carcinogenesis. Circulating tumor DNA (ctDNA) originates from tumors as a result of cancer cells undergoing"
13,page_13,"Protocol Number: v. 3.0 Date: 11 August 2020 14 apoptosis and necrosis, thereby releasing their DNA into the bloodstream. CtDNA liquid biopsies are v ery suitable for diagnosis as ctDNA can be detected in the plasma of even early -stage cancer patients. Moreover, ctDNA reflects the cumulative tumor burden as it is released in all regions of the tumor. This offers an advantage over traditional tissue biop sies, which contain only a minor part of the tumor and are not representative for tumor heterogeneity (15). The use of liquid biopsies and the analysis of ctDNA in CRC patients is not new and has b een performed in the past (16)(17-20). However, until now, a strong focus existed on the detection of tumor specific mutations, which has several limitations. First, tumor specific alterations need to be identified a priori by DNA sequencing of tumor biopsies, making it a costly and time-consum ing practice. Second, since these somatic mutations can vary from case to case, a personal assay might have to be developed. Third, the amount of mutations that are found in a given primary tumor are highly variable. For some tumors, few mutations are pres ent in the primary tumor, hence severely limiting sensitivity for plasma -based mutation detection markers. Several liquid biopsy tests have been proposed in the past (21), but all lack the sensitivity to have strong clinical utility . In cont RASt to genetic mutations, also epigenetic changes such as DNA hypermethylation of neuropeptide Y protein ( NPY) have been described in CRC (16, 22, 23) . Digital droplet PCR (ddPCR) allows to measure NPY methylation in a highly sensitive manner to determine the amount of ctDNA in plasma samples. In fact, NPY methylation is a surrogate marker for tumor burden in CRC patients. The main advantage of methylation assays is the applicability in almost every patient, while the use of mutation assays requires prior knowledge of mutations present in the tumor. Exploration of epigenetic methylation alterations in ctDNA Epigenetic changes in cancer have attracted great attention in the last years. It is widely acce pted that the initiation and progression of cancer involve epigenetic abnormalities, such as DNA methylation. Changes in DNA methylation are considered an early event in carcinogenesis (24-26) and have already been proposed for early diagnosis of cancer. In CRC in particular, aberrant methylation has been observed, allowing non -invasive population screening using blood samples (23, 27 -30) and follow -up during therapy (31-33). Methylated ctDNA in liquid biopsies is valuable in cancer prognosis and tumor response. Therefore, it is of interest to further explore the use of DNA methylation in li quid biopsies in clinical practice. Rationale Many advances in systemic therapies have significantly improved the survival of patients with CRC (34). However, there is a high variability of therapeutic responses among patients and determining the optimal personalized treatment plan is challenging. Conventional monitoring of the therapy"
14,page_14,"Protocol Number: v. 3.0 Date: 11 August 2020 15 response is based on imaging as suggested in RECIST 1.1 (35) and measurements of CEA and CA19.9 de rived from plasma . However, radiological assessments are usually limited in frequency (radiation exposure, costs, logis tics,…), ha ve a detection limit, are not suited for small metastases and cannot describe intrinsic characteristics of each tumor. Therefore, other predictive biomarkers of treatment outcomes and disease progression are of great value to enable early therapy response evaluation and early change of therapy avoiding unnecessary side effects, enhancing efficacy and minimizing costs. Quantification of ctDNA in real -time renders information on tumor characteristics and has been shown to be associated with treatment respons es in mCRC (16, 36) . Recently, our research group has shown that quantifying ctDNA through the methylation analysis of NPY in circulating DNA is a good marker for total tumor burden and can therefore be used for the follow -up of mCRC patients (22). It could be demonstrated that the amount of ctDNA in plasma, measured using NPY ddPCR methylation assays, decreased immediately (14 days) after treatment start. The amount of ctDNA remained low or undetectable in patients undergoing curative metast asectomy, while the amount of ctDNA increased in patients showing progressive disease (22). As progressive disease might be detected earlier using liquid biopsies as compared to observations by radiographic evaluation, the use of liquid biopsies might be a promising tool to guid e treatment options. The aim of this study is to determine the optimal cutoff value of the liquid biopsy test (using a ROC curve based on the data of this study). This cutoff value will be used in a follow -up study to detect progressive disease in patients with metastatic colorectal cancer treated with firs t-line FOLFOX/FOLFIRI and panitu mumab. Additionally, the follow -up trial will determine if ctDNA detects progression earlier than conventional used imaging techniques and will estimate the effect on progr ession -free survival in case therapy is guided by NPY methylation levels in liquid biopsy. Furthermore, in the LEAD -IN FOLICOLOR Trial we will exploratively compare liquid biopsies to tumor markers (CEA and/or CA19.9) in their ability to predict progressiv e disease. This innovative study will add evidence to the clinical relevance of ctDNA during treatment."
15,page_15,"Protocol Number: v. 3.0 Date: 11 August 2020 16 2 OBJECTIVE S This is a prospective, multicenter interven tional study designed to optimize the cutoff value of NPY methylation in liquid biopsies (ctDNA ) in patients with metastatic colorectal cancer receiving first- line FOLFOX/FOLFIRI and panitumumab . Primary objective The primary objective of the LEAD -IN FOLICOLOR Trial is to optimize the cutoff value of NPY methylation in liquid biopsies (ctDNA) of patients with metastatic colorectal cancer receiving first- line FOLFOX/FOLFIRI and panitumumab . Secondary objectives The secondary objective is t o determine the progression free and 9 -month survival of RAS and BRAF wild-type metastatic colorectal cancer p atients. Exploratory objectives The exploratory objectives will include, but will not be limited to the following:  To compare the use of ctDNA and CEA to predict progression .  Further exploration of ctDNA in liquid biopsies and search ing for novel biomarkers.  To explore the quality of life and the patient experience in this patient population with regard to the use of liquid biopsies for follow -up through questionnaires . This will include, but will not be limited to the following: o Burden of extra blood samples (extra blood samples during routine blood test) o Burden of CT scan with intravenous contrast o Confidence in liquid biopsy guided therapy (ctDNA analysis) compared to CT scan guided therapy o Preference be tween extra blood sample a nd CT scan (taking into account : burden, pain, time in the hospital, extra travel time to the hospital, confidence in technique …)"
16,page_16,"Protocol Number: v. 3.0 Date: 11 August 2020 17 3 STUDY ENDPOINTS Primary endpoint Using the data of this LEAD -IN study, a Receiver Operating Characteristic (ROC) curve will be developed in order to determine the optimal c utoff value for NPY methylation in liquid biopsies to predict progression on CT scan . Secondary endpoints • To determine the progression free survival in patients with metastatic colorectal cancer defined as time from inclusion to the date of first disease progression among subjects with metastatic colorectal cancer per RECIST 1.1 criteria, or death . • The 9-month survival will be determined as percentage surviving at 9 months after the start of first-line therapy . Exploratory endpoints • Explore and compare the use of NPY methylated ctDNA and CEA to predict progression • Further exploration of ctDNA in liquid biopsies and searching for novel biomarkers. • To assess the (health -related) quality of life in patients with colorectal cancer by the use of the following validated questionnaire s: EORTC QLQ -C30 and EORTC QLQ -CR29 (cfr. Appendix 15.2 & 15.3 ). • To assess the p atient experience through a questionnaire (cfr. Appendix 1 5.4 & 15.5 ). 4 STUDY POPULATION Number of centers This study is a multicenter trial of which all mCRC patients will be recruited at approximately 10 hospitals in Belgium, includ ing the Antwerp University Hospital."
17,page_17,"Protocol Number: v. 3.0 Date: 11 August 2020 18 5 SUBJECT ELIGIBILITY Investigators will be expected to maintain a screening log of all pote ntial study candidates that includes limited information about the potential candidate ( date of birth ), date of screening , and outcome of the screening process (e .g., enrolled into study, or reason for refusal to participate). Inclusion Criteria Disease related  Histologically or cytologically confirmed adenocarcinoma of the colon or rectum in subjects with unresectable metastatic (M1) disease  Starting f irst-line FOLFOX/FOLFIRI and panitumumab f or metastatic colorectal cancer  At least 1 uni -dimensionally measurable lesion of at least 10 mm per RECIST 1.1 guidelines (see Appendix 15.6) using conventional techniques ( CT scan ). Lesion must not be chosen from a previously irradiated field, unless there has been documented disease progression in that field after irradiation and prior to inclusi on. All sites of disease must be evaluated  28 days prior to the start of first - line therapy.  Wild-type RAS tumor status of the tumor tissue tested by the local hospital . This test must be performed during screening phase.  Wild-type BRAF tumor status of the tumor tissue tested by the local hospital . This test must be performed during screening phase.  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 . Demographic  Man or woman 18 years of age or older at the time the informed consent is obtained . Laborat ory To be performed ≤ 1 4 days prior to the start of first -line therapy , unless otherwise specified: 5.1.3.1 Hematologic function within the following limits: o Absolute neutrophil count (ANC) ≥ 1.5 x 109/L o Platelet count ≥ 100 x 109/L (without platelet transfusion  14 days prior to start therapy ) o Hemoglobin (Hgb) ≥ 9.0 g/dL"
18,page_18,"Protocol Number: v. 3.0 Date: 11 August 2020 19 5.1.3.2 Renal function within the following limits: o Creatinine clearance (GFR)  50 mL/min calculated by the Cockcroft -Gault method as follows:  Male creatinine clearance = (140 – age in years) x (weight in kg) / (serum creatinine in mg/dL x 72)  Female creatinine clearance = (140 – age in years) x (weight in kg) x 0.85 / (serum creatinine in mg/dL x 72) o Urina ry protein ≤ 30 mg by urinalysis or ≤ 1+ by dipstick or urine protein creatinine (UPC) ratio ≤ 0.5 by urinalysis (unless excretion of < 1000 mg of protein per day as determined by 24 -hour urine collection).  Note: UPC ratio of spot urine is an estimation of the 24 urine protein excretion - a UPC ratio of 1 is roughly equivalent to a 24 -hour urine protein of 1 gm. UPC ratio is calculated using one of the following formula: [urine protein]/[urine creatinine] - if both urine protein and creatinine are reporte d in mg/dL. [(urine protein) x0.088]/[urine creatinine] - if urine creatinine is reported in mmol/L. 5.1.3.3 Hepatic function within the following limits: o Total bilirubin ≤ 1.5 x ULN o Alkaline phosphatase ≤ 2.5 x ULN (if liver metastases, ≤ 5 x ULN) o Aspartate aminotransfe rase (AST) ≤ 2.5 x ULN (if liver metastases, ≤ 5 x ULN)  o Alanine aminotransfe rase (ALT) ≤ 2.5 x ULN (if liver metastases, ≤ 5 x ULN)  5.1.3.4 Metabolic function within the following limits: o Magnesium ≥ lower limit of normal  5.1.3.5 Coagulation function within the following limits: o Partial thromboplastin time (PTT)/activated partial thromboplastin time (aPTT) ≤ 1.0 x ULN and international normalized ratio (INR) < 1.5, unless the subject is on therapeutic anticoagulation therapy. Patients on therapeutic anticoagulation are eligible if the following criteria are met:  The subject has an in -range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or is on a stable dose of low molecular weight heparin.  The subject has no active bleeding or p athological condition that carries high risk of bleeding (e .g., tumor involving major vessels or known varices) 5.1.3.6 Negative pregnancy test o Serum pregnancy test ≤ 14 days prior to start therapy (for women of childbearing potential only)"
19,page_19,"Protocol Number: v. 3.0 Date: 11 August 2020 20 Exclusion Criteria Disease Related  History of prior or concurrent central nervous system (CNS) metastases  History of other malignancy, except: o Malignancy treated with curative intent and with no known active disease present for ≥ 3 years prior to the start of first -line therapy and felt to be at low risk for recurrence by the treating physician o Adequately treated non -melanomatous skin cancer or lentigo maligna without evidence of disease o Adequately treated cervical carcinoma in situ without evidence of disease o Prostatic intraepithelial neoplasia without evidence of prostate cancer  Cancer Therapy o Prior chemotherapy or other systemic anticancer therapy for the treatment of metastatic colorectal carcinoma including but not limited to bevacizumab and anti -EGFR therapy (e .g. cetuximab, panitumumab, erlotinib, gefitinib, lapatinib)  Prior adjuvant chemotherapy (including oxaliplatin therapy) or other adjuvant systemic anticancer therapy including but not limited to bevacizumab and anti - EGFR therapy (e .g. cetuximab, pa nitumumab, erlotinib, gefitinib, lapatinib) for the treatment of colorectal cancer ≤ 6 months prior to the start of first -line therapy with the following exceptions: o Subjects may have received prior fluoropyrimidine therapy if administered solely for the p urpose of radiosensitization for the adjuvant or neoadjuvant treatment of rectal cancer  Radiotherapy ≤ 14 days prior to start therapy. Subjects must have recovered from all radiotherapy -related toxicities.  Unresolved toxicities from prior anti -cancer therapy that, in the opinion of the investigator, excludes subject from participation Other Medications  Infection requiring a course of systemic anti -infectives that was completed ≤ 14 days before start therapy (exception can be made at the judgment of th e investigator for oral treatment of an uncomplicated urinary tract infection (11)) General  Significant cardiovascular risk: o Myocardial infarction, grade 2 or greater peripheral vascular disease , arterial thrombotic event, visceral arterial ischemia, cerebrovascular ischemia, transient ischemic attack, percutaneous transluminal coronary angioplasty/stent or unstable angina ≤ 24 weeks prior to start"
20,page_20,"Protocol Number: v. 3.0 Date: 11 August 2020 21 therapy o Symptomatic and/or serious uncontrolled cardiac arrhythmia o Symptomatic congestive heart failure (New York Heart Association Class III or IV) o Uncontrolled blood pressure defined as > 150 mmHg systole or > 90 mmHg diastole. Anti -hypertensiv e medications are allowed if hypertension is stably controlled at the time of start therapy . o Pulmonary embolism, deep vein thrombosis, or other significant venous event ≤ 8 weeks before start therapy  History of interstitial lung disease (e .g., pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline CT scan  Active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as ≥ CTC grade 2, [CTCAE version 5.0])  Peripheral sensory neuropathy (≥ CTC grade 2 [CTCAE version 5.0]  Any co -morbid disease or condition that could increase the risk of toxicity (such as clinically significant ascites)  Subjects known to be human immunodeficiency virus (HIV) positive or known to have chronic or active hepatitis B or C infection  Subject is currently enrolled in, or ≤ 30 days has passed since subject completed another investigational device or drug study(s), or subject is receiving other investigational agent(s)  Women of child -bearing potential is evidently pregnant (e .g., positive HCG test) or is breast feeding  Men and women of childbearing potential who do not consent to use adequate contraception during the course of the study. Adequate contraceptive precautions includes double barrier contra ceptive methods (e.g., diaphragm and condom) or abstinence  History of any medical or psychiatric condition or addictive disorder, or laboratory abnormality that, in the opinion of the investigator, may increase the risks associated with study participation or study drug administration or may interfere with the conduct of the study or interpretation of study results  Subject has previously been included into this study  Subject unwilling or unable to comply with study requirements ( e.g., will no t be available for follow -up assessment)  Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures (except for subjects with a legally acceptable representative)"
21,page_21,"Protocol Number: v. 3.0 Date: 11 August 2020 22 6 STUDY SCHEDULE AND PROCEDURES Screening p eriod / eligibility check The screening period is also referred to as ‘M b’ (cfr. Appendix 15.1). Pre-screening The indication s of eligibility (cfr. 5.1.1 & 5.1.2) :  Wild-type RAS tumor status (of tumor tissue)  Wild-type BRAF tumor status (of tumor tissue)  Unresectable mCRC  First-line treatment: FOLFOX/FOLFIRI + panitumumab  ECOG performance status of 0 or 1  Man or woman 18 years of age or older at the time t he informed consent is obtained  Not meeting the exclusi on criteria (cfr. 5.2) Note1: Subjects that are determined not eligible after pre-screening must be listed as screen failure together with the reason for screen failure. Complete the eCRF ‘ End of Study Form’ . Signing of Informed Consent Potentially e ligible subjects (cfr. 6.1.1) are asked to sign the informed consent f orm (ICF). Only subjects who have signed the ICF will enter into the post-screening phase . Note1: Subjects that are determined eligible after p re-screening , but who do not wish to part icipate should be listed as screen failure together with the reason for screen failure . Complete the eCRF ‘End of Study Form’. Note2: The ICF must be signed < 28 days before the start of the first -line therapy. Post-screening To check the hematologic, renal, hepatic, metabolic, and coagulation function of the patient (cfr. 5.1.3 Laboratory), 1 EDTA tube must be sample d within 14 days before the start of the first -line therapy. The EDTA tube will be analyzed in the local hospital, i.e. the hospital where the patient will be treated. If the laboratory criteria (as described in 5.1.3 Laboratory ) are also met, the subject is eligible to include. Note1: If the CT scan at diagnosis (CT 0) has been performed more than 28 days before the start of the first -line therapy, an additional CT scan need s to be performed < 28 days before the start of the first -line therapy ."
22,page_22,"Protocol Number: v. 3.0 Date: 11 August 2020 23 Note2: Subjects that are determined not eligible after post-screening must be listed as screen failure together with the reason for screen failure. Complete the eCRF ‘End of Study Form’. Inclusion Subjects who meet all inclusion criteria during the pre- and post -screening phase are included in the tria l. From now on, t he patient’s study identification number (ID) must be used to identify the subject throughout the entire clinical study. This unique study ID is automatically assigned by the Electronic Data Capture System “Castor EDC ” (cfr. 7.4) . The study ID consists of three parts: the trial ID (abbreviation of the trial ‘LIFT’ ), followed by the center ID (abbreviation of the participating center) and the patient ID ( three -digit number ). The sponsor assigns the abbreviation of the participating center. Note1: For example, a n eligible patient in the Antwerp University Hospital could be assigned the study ID ‘ LIFT_UZA_001 ’. As soon as the patient is officially included , the patient is asked to complete the Quality of Life questionnaire, including the EORTC QLQ -C30 and QLQ -CR29 (cfr. Appendix 15.2 & 15.3) . This questionnaire must be completed by the day on which first -line therapy starts (M0) at the latest. Start first -line therapy Patients will receive FOLFOX/FOLFIRI and panitumumab with therapy guidance according to CT scan s. The day on which the first -line therapy starts is named as ‘M0’. First-line therapy (FOLFOX/FOLFIRI and panitumumab) is planned to be administered every 2 weeks (± 3 days) (not including the time to recover from toxicities). On the same day of, but before the administration of the first chemotherapy cycle, 3 liquid biopsies (LB 0, LBa en LB b) must be sampled. LB0 will be used to measure the ctDNA level at baseline, and LB a and LB b will be used for further research . The 3 LB’s must be transported to CMG Antwerp (cfr. 6. 5.3). Follow -up LB sampling will occur biweekly (not taking into account the time to recover from toxicities , therapy pause or delay ) up to and including 9 months after the start of first -line therapy . The collection of the liquid biopsy samples will move along with the first day of administrat ion of a new chemotherapy cycle. Each time a next therapy cycle starts, three liquid biopsies should be collected before the therapy is administered. These three liquid biopsies include one Streck tube to measure the ctDNA level, and two Streck tube s that will be used for further research or, if necessary, as a"
23,page_23,"Protocol Number: v. 3.0 Date: 11 August 2020 24 reserve sample. The LBs should be named after the applicable chemotherapy cycle; LB 2 for the 2nd chemotherapy cycle , LB3 for the 3th chemotherapy cycle …). It is advised to combine the LB sampling with a routine blood test (standard of care) . When the last liquid biopsies have been collected (i.e. on the day of, but before the administration of the last therapy cycle that takes place in the 9 months after starting first -line therapy ), the LB sampli ng stops. The patient has to complete the EORTC QLQ -C30, QLQ -CR29, and the patient experience questionnaire (cfr. Appendix 15.4 & 15.5). A time window of 7 days after M9 is allowed to complete the questionnaire. After this, the treating physician will cont inue the patients’ treatment conform the standard clinical practice. Tumor response assessment will be performed by the local investigator per modification of RECIST 1.1 guidelines on bimonthly CT scans (not taking into account the time to recover from toxicities, therapy pause or delay) together with a CEA test, up to and including the next imaging (CT scan) that is performed after the collection of LBs has stopped . Thus, the CT scans will also move along with the administered chemotherapy cycles. In cas e of biweekly administration of therapy without delay or therapy pause, the bimonthly CT scans and CEA test correspond to the moments of evaluation of chemotherapy cycle 4, 8, 12, 16 and 20. Treatment is changed upon CT scan results (conform standard clinical practice) . With the exception of what is described in chapter 6. 8, the subjects will be followed (and thus the collection of follow -up data continues ) until the next imaging (CT scan) that is performed after the collection of LBs ha s stopped , provided that this imaging is performed within 11 months of follow -up (cfr. Appendix 15.1). The imaging refers to the CT scan that aims to evaluate the last administered chemotherapy cycle that was given within 9 months after the start of first -line therap y. If, for any reason , this CT scan will be performed > 11 months after the start of first -line therapy, or no CT scan will be performed after the last collection of LBs, the study ends when the subject has reached 11 months of follow -up. Notes:  In the event that chemotherapy is delayed due to poor blood results, and 3 liquid biopsies were already collected together with the routine blood test, 3 new liquid biopsies must be collected on the same day of, but before the administration of the newly s cheduled chemotherapy cycle .  No limitation is imposed on the duration of therapy pause . As soon as the therapy is restarted, the LB sampling continues as described in the protocol."
24,page_24,"Protocol Number: v. 3.0 Date: 11 August 2020 25  If the therapy changes (i.e. stop FOLFOX/FOLFIRI and panitumumab) throughou t the follow -up period, the follow -up procedure continues according to the protocol (i.e. LB- sampling on the first day of administration of the new therapy cycle up to and including 9 months after the start of the first -line therapy ).  If a metast asectomy is planned, 1 liquid biopsy must be taken on the day of, but before surgery. A second liquid biopsy must be collected within the next 2 days, excluding the day of surgery . After this, no more liquid biopsy samples need to be collected.  After progression on CT scan , the patient will continue with standard of care as decided by the treating physician. The follow -up schedule is maintained. The LB sampling still continues up to and including 9 months after the start of first -line therapy but will then be linked/combined with the new therapy.  If it is appropriate to perform a MRI scan during follow -up, this should be reported in the eCRF. Sample collection RAS and BRAF wild-type tumor status The local hospital is responsible for analyzing the wild-type RAS and BRAF tumor status of the tumor tissue. CEA level The local hospital is responsible for analyzing the bimonthly CEA level, which has to be reported in the appropriate eCRF . Liquid biopsies The sponsor provides pre -prepared kits, each cons isting of three Streck tubes for liquid biopsy sampling. The pre -prepared kit must be used when collecting the biweekly liquid biopsies. All samples will be transported to the Center for Medical Genetics (CMG) in Antwerp for NPY methylation analyses. The local investigator (team) is responsible for registering the samples in a specific Excel -file, also provided by the sponsor, which has to be sent by e -mail to the CMG Antwerp. The samples are preferably sent on the day of collection (if not possible; n o later than the following day) with a transport company to the CMG. Delivery is only possible on workdays (Monday to Friday) between 8:00 am and 4:30 pm. Samples that are collected on Friday and that cannot be sent the same day due to circumstances must be transported to the CMG next Monday. Until then, the liquid biopsy samples must be stored between 6°C and 37°C."
25,page_25,"Protocol Number: v. 3.0 Date: 11 August 2020 26 Note1: In the case of metastasectomy , 1 liquid biopsy must be taken on the day of, but before surgery. A second liquid biopsy must be collected within the next 2 days, excluding the day of surgery. However, both LB samples must be transported together to the CMG . Both samples are preferably sent on the day of collection of the seco nd LB samp le (if not possible; not later than the following day). If the seco nd sample is collected on Friday and it is not possible to send both LBs the same day, the samples must be transported to the CMG next Monday. Note2: In the event that chemotherapy is dela yed due to poor blood results, and 3 liquid biopsies were already collected together with the routine blood test, 3 new liquid biopsies must be collected on the same day of, but before the administration of the newly scheduled chemotherapy cycle . All LB samples (a total of 6 Streck tubes) must be transported together to the CMG . Note3:The Sponsor decides which transport company to work with. Questionnaire The questionnaire is available both on paper and digitally. The patient is free to choose wh ich option he/she prefers. Paper questionnaires must be entered into the database Castor EDC by the local or central study team, and must be saved on site. Digital questionnaires are available via a web link, which Castor EDC automatically sends to the pat ient via email. Completed digital questionnaires are automatically imported into the patient record in Castor EDC. Completing the digital questionnaire is only possible if the patient explicitly indicates in the Informed Consent whether he/she agrees to sh are his/ her email address with the Sponsor . Protocol compliance Protocol compliance will be checked after inclusion of the first 20 patients. This approach will guarantee that no important aspects are overlooked in order to follow the protocol faultless. The flow of collecting and transport of blood samples, communication of both blood results and CT evaluation , and completion of the eCRFs will be checked for unexpected barriers. End of study Study completion The study is completed after performing the first imaging ( CT scan ) following the last collection of liquid biopsies according to the study protocol , provided that this imaging is performed within 11 months of follow -up. However, a maximum follow -up period of 11 months applies to all study"
26,page_26,"Protocol Number: v. 3.0 Date: 11 August 2020 27 patients, regardless of whether or not the first imaging following the last collection of liquid biopsies has been performed. When study completion is reached , the collection of follow -up data stops. (S)AE reporting continues until 14 days after study completion. Note1: In case of biweekly administration of therapy without delay or therapy pause, the moment of study completion corresponds to the 10th month of fo llow-up. Changes in a patient’s condition This section refers to (1) c hanges in a patient’s condition that renders the patient not suitable for further treatment /participation in the judgment of the investigator , or (2) m ajor protocol violation or discovery of information that, if previously known, would have rendered the patient ineligible for study . 6.8.2.1 Before 9 months of follow -up The collection of liquid biopsies stops. The patient has to complete the 2nd questionnaire including the EORTC QLQ -C30, QLQ -CR29, and the patient experience questionnaire (cfr. Appendix 15.4 & 15.5). A time window of 7 days afte r end of study is allowed to complete the questionnaire. The collection of follow -up data (i.e. (serious) adverse event reporting, chemotherapy information, response imaging and CEA level ) continues until 11 months of follow -up (i.e. 11 months after M0) is reached. 6.8.2.2 After 9 months of follow -up The collection of liquid biopsies has already stopped after M9. The collection of follow -up data (i.e. (serious) adverse event reporting, chemotherapy information, response imaging and CEA level ) continues until the next imaging (CT scan) that is performed after the collection of LBs has stopped (at M9) . If, for any reason, this CT scan will not be performed, the collection of follow -up data continues until 11 months of follow -up is reached. Metastasectomy In the case that the patient will undergo metastasectomy, one l iquid biopsy must be taken on the day of, but before surgery. A second liquid biopsy must be collected within the next 2 days , excluding the day of surgery. 6.8.3.1 Before 9 months of follow -up The furt her collection of liquid biopsies stops. The patient has to co mplete the 2nd questionnaire including the EORTC QLQ -C30, QLQ -CR29,"
27,page_27,"Protocol Number: v. 3.0 Date: 11 August 2020 28 and the patient experience questionnaire (cfr. Appendix 15.4 & 15.5). A time window of 7 days after end of study is allowed t o complete the questionnaire. The collection of follow -up data (i.e. (serious) adverse event reporting, chemotherapy information, response imaging and CEA level ) continues until 11 months of follow -up is reached. 6.8.3.2 After 9 months of follow -up The further col lection of liquid biopsies stops. The collection of follow -up data (i.e. (serious) adverse event reporting, chemotherapy information, response imaging and CEA level ) continues until the next imaging (CT scan) that is performed after the collection of LBs has stopped at 9 months of follow -up. If, for any reason, this CT scan will not be performed, the collection of follow -up data continues until 11 months of follow -up is reached. Death When a p atient dies , all efforts should be made to complete and report the observati ons as thoroughly as possible. Withdrawal of consent Patients can leave the study at any time for any reason if they wish to do so without any consequences. Should a patient decide this by withdrawal of consent , all efforts will be made to complete and report the observations as thoroughly as possible. No further data (including the questionnaire) and liquid biopsies will be collected after the date of withdrawal from study. Data that was already collected will be stored and used for analysis. The Investigator should contact the patient or a responsible relative by telephone or through a personal visit to establish as completely as possible the reason for the withdrawal. A complete final evaluation at the time of the patient’s withdrawal should be made with an explanation of why the patient is withdrawing from the study. Withdrawn consent with data withdrawal Patient withdraws informed consent and requests to delete all of his/her previously collected data from the study . No further data (including the questionnaire) and liquid biopsies will be collected after the date of withdrawal from study. Lost to follow -up In the case of patients who miss scheduled visits, several attempts should be made by the site to contact these patients for follow -up information. The collection of follow -up data is extremely important regarding the reliable estimation of study endpoints, therefore at least 3 attempts within"
28,page_28,"Protocol Number: v. 3.0 Date: 11 August 2020 29 a reasonable extent of time s hould be made to try to contact the patients if they do not attend clinic visits. If any of the trial patients are lost to follow -up, contact will initially be attempted through the trial research nurse or the lead investigator at each center . Where this a ttempt is unsuccessful, the patient’s general practitioner will be contacted and asked to contact the patient or her/his family and provide follow -up information to the recruiting center . It is only after sufficient attempts at contact ing the patient have been unsuccessful, that a patient may be declared “Lost to follow -up”. The collection of follow -up data (i.e. (serious) adverse event reporting, chemotherapy information, response imaging and CEA level) stops as soon as the patient has been declared ‘lost to follow - up’. Duration of the study Inclusion of patients in this trial starts when all necessary ethical approvals have been obtained , and the Clinical Trial Agreement has been signed . The subject accrual period runs until the predetermined number of study patients is reached (i.e. 60 subjects) . First-line therapy is administered at the start of the study (i.e. M0 or chemotherapy cycle n°1 ). The study ends for the patient when the first imaging (CT scan) is perfo rmed following the last collection of LBs according to the study protocol , when a follow -up period of 11 months is reached, after surgery (metastasectomy), after withdrawal of the written consent or when the patient dies (cfr. 6.8). Early study termination The Sponsor may terminate this study at any time. Reasons for termination may inc lude, but are not limited to the following:  Insufficient subject enrolment.  Any information becoming available during the study that substantially changes the expected benefi t of the study . The subject accrual period stops immediately. However, the follow -up of previously enrolled subjects continues according to the protocol. The collection of LBs stops as soon as 9 months of follow -up is reached (except for metastasectomy cfr. 6.8.3, and death). At M9, the patient has to complete the EORTC QLQ -C30, QLQ -CR29 and the patient experience questionnaire (cfr. Appendix 15.4 & 15.5). A time window of 7 days after M9 is allowed to complete the questionnaire. The collection of follow -up data (i.e. adverse event reporting, chemotherapy information, response imaging and CEA level ) continues until the next imaging (CT scan) that is performed after the collection of LBs has stopped, or when 11 months of follow -up is reached ."
29,page_29,"Protocol Number: v. 3.0 Date: 11 August 2020 30 7 METHODOLOGY Study schedule The complete schedule of assessments is outlined in Table 1. Additional assessments, such as urinalysis or other laboratory assessments, can always be performed by the treating physi cian if deemed necessary. A dditional CT scan s can also be made, for example when the treating physician has clinical indications for progression. Results from additional tests or data from additional visits (for example if requested by the patient) will be collected for the study. Study visits in the hospital wil l take place in the treating hospital of the patient. Table 1. Schedule of assessments Pre-screening Post-screening Start first -line therapy - M0 M0 + every 2 weeks▲ (up to and including M9) M0 + every 8 weeks EOS: study completion (i.e. first CT scan after last LB collection∆) EOS: metastasectomy, changes in patient’ s condition EOS : withdrawal, death , lost to follow -up Inclusion/exclusion criteria X X Informed consent X Demographics X X ECOG X X X X¤ Medical history X Pregnancy test■ X Laboratory assessments X Xπ Xπ CT scan X* X X∆ Blood sample for LBa and LB b X2 Blood sample for LBx X1 X3 X3 X2** CEA level X X X∆ Therapy information X X X X X"
30,page_30,"Protocol Number: v. 3.0 Date: 11 August 2020 31 Quality of Life Questionnaire (EORTC QLQ -C30 + QLQ -CR29 X∞ X♦ X¥ Patient Experience Questionnaire X♦ X¥ (S)AE’s Continuously Documentation + reason end of study X X X ∞ To be completed as soon as the patient is included, and by the day on which first -line the rapy starts (M0) at the latest ¥ To be completed only if < 9 months follow -up ▲ At the start of, but before the administration of each chemotherapy cycle (cfr. 6.4. Follow -up, Notes) ■ Serum pregnancy test ; to be performed ≤ 14 days prior to start therapy (for women of childbearing potential only) ♦ To be completed only after reachi ng 9 months of follow -up (i.e. last collection of LBs) ∆ If, for any reason, no CT scan will be performed afte r the collection of LBs have stop ped, study completion is reached after 11 months of follow -up π It is advised to combine the LB sampling with a routin e blood test (standard of care) ¤ ECOG should not be determined in case of death * Only if diagnostic CT scan is performed > 28 days before the start of the first-line therapy ** Only in the case of metastasectomy: collection of o ne LB sample on the day of surgery but before the operation, and a sec ond LB sample within the next 2 days, excluding the day of surgery 1 Only one blood sampl e (Streck tube) is needed 2 Two blood samples (Streck tubes) are needed 3 Three blood samples (Streck tubes) are needed Assessments and study visits Screening period (Mb) Pre-screening  Eligibility check (inclusion/exclusion criteria) including BRAF and RAS WT  Demographics (age)  ECOG  Medical history  Therapy information Written informed consent should be obtained prior to enrolment in the post-screening phase :  Demographics (age, sex, ethnic origin)  Therapy information  Serum p regnancy test ≤ 14 days prior to start therapy (for women of childbearing potential"
31,page_31,"Protocol Number: v. 3.0 Date: 11 August 2020 32 only)  Laboratory assessments: hematology ( erythrocytes/haematocrit, hemoglobin, neutrophils, thrombocytes, leukocytes, leukocyte formula), biochemistry (creatinine, creatinine clearance, ureum, sodium, potassium, chloride, bicarbonate, calcium, phosphor, magnesium, uric acid, CRP, total protein, albumin, glucose (serum), LDH, AST(GOT), ALT(GPT), alkaline phosphatase, GGT, amylase, bilirubin + fractions, cholesterol, triglycerides), liver fun ction tests (P TT, aPTT, INR), TSH, urinalysis (urinary protein or UPC)  CT scan  only if diagnostic CT scan is performed > 28 days before the start of first -line therapy  CEA level at baseline Start first -line therapy (M0)  Streck tubes for LB0, LB a and LBb  Questionnaire (EORTC QLQ -C30 + QLQ -CR29 ): to be completed as soon as the patient is included, and by the day on which first -line therapy starts (M0) at the latest  Therapy information  If applicable: (S)AE reporting M0 + every 2 weeks (up to and including M9) Note: Biweekly LB sampling is only applicable if there is no therapy pause or delay; LB sampling will move along with the start of a new chemotherapy cycle .  Chemotherapy cycle 2, 3, 4, ..., 19  Laboratory assessments: routine blood test  The routine blood test should include, but will not be limited to the following: o Hematology o Erythrocytes/hematocrit o Hemoglobin o Neutrophils o Thrombocytes o Leukocytes o Leukocyte formula  Collection of liquid biopsies o Streck tube for LBx"
32,page_32,"Protocol Number: v. 3.0 Date: 11 August 2020 33 o Extra Streck tube s for further research  Therapy information  Questionnaire: Quality of Life ( QLQ -C30 + QLQ -CR29 ) & Patient Experience : to be completed when reaching 9 months of follow -up (i.e. last collection of LBs)  If applicable: (S)AE reporting M0 + every 8 weeks Note: Bimont hly CT scan is only applicable if there is no therapy pause or delay; CT scans will move along with the administered chemotherapy cycles .  Laboratory assessments: routine blood test ( cfr. 7.2. 3)  CT scan (last imaging to be performed is the next CT scan following the last LBs that have been collected at M9)  CEA level (up to and including the next CT scan following the last LBs that have been collected at M9)  Collection of liquid biopsies o Streck tube f or LB x (up to and including M9) o Extra Streck tube s for further research (up to and including M9)  Therapy information  If applicable: (S)AE reporting End of study [EOS] in case of study completion  EOS is reached after performing the next imaging (CT scan) following the last liquid biopsies that have been coll ected at M9 o CT scan o CEA level  ECOG  Therapy information  If applicable: (S) AE reporting until 14 days after EOS  Confirmation and documentation reason for end of study Note: If, for any reason, no CT scan will be performed after the collection of LBs have stopped, study completion is reached after 11 months of follow -up."
33,page_33,"Protocol Number: v. 3.0 Date: 11 August 2020 34 End of study in case of metastasectomy  Collection of liquid biopsies o One Streck tube on the day of su rgery but before the operation o Second Streck tube within the next 2 days, exc luding the day of surgery  ECOG  Therapy information  Questionnaire: Quality of Life ( QLQ -C30 + QLQ -CR29 ) & Patient Experience : to be completed if metastasectomy takes place before 9 months of follow -up  If applicable: (S) AE reporting until 14 days after EO S  Confirmation and documentation reason for end of study End of study in case of changes in a patient’s condition  ECOG  Therapy information  Questionnaire: Quality of Life ( QLQ -C30 + QLQ -CR29 ) & Patient Experience : to be completed if metastasectomy takes pla ce before 9 months of follow -up  If applicable: (S) AE reporting until 14 days after EO S  Confirmation and documentation reason for end of study End of study in case of withdrawal  ECOG  Confirmation end of study + documentation reason of withdrawal End of study in case of lost to follow -up  ECOG  Confirmation end of study + documentation of lost to follow -up End of study in case of death  Confirmation end of study + documentation reason of death"
34,page_34,Protocol Number: v. 3.0 Date: 11 August 2020 35 Summary of study procedures Summary of study specific procedures The procedures listed and described in this section are specific to the study and are not part of standard clinical care. • Screening period o Informed Consent Form o eCRF completion o Specific laboratory assessments (cfr. 5.1.3) < 14 days before start therapy o Serum p regnancy test (if applicable) o Additional CT scan if the CT scan at diagnosis (CT 0) is performed > 28 days before start therapy o Quality of Life questionnaire • Start first -line therapy o Collection of liquid biopsies (LB) o Transportation of LBs to CMG Antwerp o eCRF completion • Follow -up o Biweekly collection of liquid biopsies (3 samples) up to and including M9  Exceptions: delay of therapy (cfr. 6.4. Notes) and metastasectomy (cfr. 6.8.3) o Transportation of LBs to CMG Antwerp o Bimonthly CEA test up to and including the next imaging (CT scan) following the last LBs that have been collected at M9 o eCRF completion o M9: Quality of Life and Patient Experience questionnaire Summary of standard of care study procedures • Screening period o CEA level at baseline • Start first -line therapy o First-line therapy FOLFOX/FOLFIRI and panitumumab planned to be administered every 2 weeks (± 3 days) o Bimonthly CT scan • Follow -up o Routine blood test before the start of new chemotherapy cycle o Tumor response assessment per modifica tion of RECIST 1.1 guidelines on bimonthly CT scan o Decision of the treating physician to change therapy according to the outcome of the bimonthly CT scan o Decision of the treating physician to delay chemotherapy o Decision of the treating physician to perfor m a metastasectomy
35,page_35,"Protocol Number: v. 3.0 Date: 11 August 2020 36 Data collection and data storage encoding Clinical information about the patients, collected at the study visits in the hospital or by the external partner will be encoded and put in an eCRF of the Electronic Data Capture System “Castor EDC”. The management of this central database is performed by the Multidisciplinary Oncology Centre Antwerp (MOCA) of the Antwerp University Hospital in Edegem, Belgium. UZA is owner of the database and the information will be kept for at least 30 years after study termination. Patient reported outcomes are collected through questionnaires on a web -based customized survey (created in Castor EDC) meeting the requirements of the privacy commission. The results from the analysis of liquid biopsies will be collected in the eCRFs in Castor EDC, as well as in an encrypted Exc el-file on a shared IT -platform of UZA . Only investigators of CMG Antwerp and MOCA will have access to this encrypted document. All individual patient documentation is stored encoded and the same code is used in both the central database with CRFs and the web -based survey. All liquid biopsies will be stored at the biobank of UZA. Biobank specimens and the patient’s associated clinical data will be stored for 30 years. The management of intellectual property rights and the ownership of the data is discussed in de tail in the contract documents. Evaluation of data Tumor response evaluation CT scan : Image analysis will be performed locally and also the decision about progression wil l be made in the treating center . ctDNA analysis As described, liquid biopsies contain, except for ctDNA, circulating DNA originating from non- malignant cells. One can differentiate ctDNA from non-malignant DNA by selecting on a base of NPY methylation (22). The blood samples will be centrifuged according to protocol (two -step high speed). Hereafter, the plasma fraction and cell pellet will be stored and analyzed separately. To enable an objective analysis, the CMG Antwerp is blinded and will therefore not be aware of the disease status of the study patients during the course of the study. The results of the NPY methylation analyses will be reported to the central study coordi nator of the Antwerp University Hospital. 8 STATISTICAL CONSIDERA TIONS Sample size calculation The primary endpoint is the optimal cutoff value of NPY methylation to discriminate between"
36,page_36,"Protocol Number: v. 3.0 Date: 11 August 2020 37 progressive and non -progressive disease (as determined by CT). For the sample size calculation, we have based ourselves on the Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) curve using NPY methylation. In order to construct a 95% confidence interval for the AUC of width 0.2 and assuming an AUC of 0.9 we need at least a group of 27 patients with progressive disease and a group of 27 patients without progressive disease. Assuming a median PFS of 9 months, we will need to include 54 patients and follow them up for 9 months. However, it is expected that about 10 -15% of the study population ( RAS and BRAF WT unresectable mCRC) may become resectable by conversion therapy (FOLFOX/FOLFIRI and panitumumab) (37-39). Taking this into account, the total number of patients to be included is 60. Primary analysis To determine the optimal cut off value of the NPY methylation to discriminate between progressive and non -progressive disease (as determined by CT), we will develop a Receiver Operating Characteristic (ROC) curve with data of this lead -in study. ROC curves show the trade -off between sensitivity and specificity and the Area Under the Curve (AUC) is considered as an index of accuracy. The AUC will be calculated, and the optimal cutoff will be determined. Secondary analysis  In the primary analysis we compare NPY methylation values and progression status (as determined by CT) taken at the same time point. As a secondary analysis we will study if NPY methylation values at earlier time points can predict progression status later on. For this also ROC -curves will b e used.  A logistic regression model predicting progressive disease using NPY methylation values as a predictor will be considered. This model will allow correction for other variables (e.g. age).  To determine the progression free survival in patients with metastatic colorectal cancer defined as time from inclusion to the date of first disease progression among subjects with metastatic colorectal cancer per RECIST 1.1 criteria, or death . Progression free survival will be presented with a Kaplan -Meier curve a nd median progression free survival with corresponding 95% confiden ce interval will be reported.  For the 9-month survival the percentage alive at 9 months after start of first -line therapy will be reported with corresponding 95% confidence interval. Exploratory analysis  In this study, we will exploratively compare the use of ctDNA and CEA to predict progression , through logistic regression models. To compare these two methods, we will take sensitivity,"
37,page_37,"Protocol Number: v. 3.0 Date: 11 August 2020 38 specificity, negative predictive value and positive predictive value into account. This study will result in useful preliminary data that can be further studied in future projects. Moreover, this data might lead to more correct determination of effect size s, which can be used for power calculations for future studies.  The further exploration of ctDNA in liquid biopsies and search for novel biomarkers can result in important leads that can be systematically studied in deeper extent in further projects.  We wi ll exploratively study patient experience through short questionnaires. The results of these questionnaires can lead to interesting qualitative information which can be used to optimize patient care and/or the protocol of the next (randomized) phase of the FOLICOLOR trial.  The quality of life and the patient experience measured by the questionnaires will be reported with descriptive statistics."
38,page_38,"Protocol Number: v. 3.0 Date: 11 August 2020 39 9 SAFETY REPORTING Ethical Committee The investigator will inform the subjects and the reviewing accredited Ethic al Committee if anything occurs, on the basis of which it appears that the disadvantages of participation may be significantly greater than was foreseen in the research proposal. The study will be suspended pending further review by the accredited Ethical Committee, except insofar as suspension would jeopardize the subjects’ health. The investigator will take care that all subjects are kept informed. Adverse events Definition Adverse Event (AE) Adverse events are defined as any undesirable experience occurrin g to a subject during the study that need not be related to treatment . An adverse event is any unfavorable, unintended diagnosis, symptom, sign (including abnormal laboratory finding), syndrome, or disease that occurs during the study, having been absent at baseline, or –if present at baseline - appears to worsen. All adverse events , including chemotherapy toxicities of all grades , reported spontaneously by the subject or observed by the investigator or his staff will be recorded. Definition Unexpec ted Adverse Event (UAE) An unexpected adverse event is defined as an adverse event that is not mentioned in the protocol or consent documents , or an AE that has not been seen before. Additionally, unexpected AEs in this study can be considered as unanticip ated problems involving risks to study participants and others as an event that meets all of the following criteria: 1. unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described in the protocol -related docume nts, such as the informed consent document; and (b) the characteristics of the subject population being studied; 2. related or possibly related to participation in the research (i.e. the incident, experience, or outcome may have been caused by the procedures involved in the research). Recording of AEs All AEs, reported spontaneously by the subject or observed by the investigator or his staff will be recorded on the AE form of the CRF with the following information: 1. The severity grade according to the NCI -CTCA E version 5.0, published November 27 , 2017 (The complete document can be reviewed and downloaded from the following internet site:"
39,page_39,"Protocol Number: v. 3.0 Date: 11 August 2020 40 https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quic k_Reference_5x7.pdf (1=mild, 2=moderate , 3=severe, 4=life threatening) 2. Whether it constitutes a n UAE or SAE All AEs should be treated appropriately. Treatment may include one or more of the following: no action taken (i.e. further observation only); chemotherapy temporarily interrupted; chemo therapy permanently discontinued due to this AE; concomitant medication given; non -drug therapy given; patient hospitalized/patient’s hospitalization prolonged. The action taken to treat the AE should be recorded on the AE CRF. Once an AE is detected, it should be followed until its resolution or until it is judged to be permanent, and assessment should be made at each visit (or more frequently, if necessary) of any changed in severity, the interventions required to treat it, and the outcome. Follow -up of adverse events All adverse events will be followed until they have abated, or until a stable situation has been reached. Depending on the event, follow up may require additional tests or medical procedures as indicated, and/or referral to the general phy sician or a medical specialist. Serious Adverse Events Definition Serious Adverse Event A serious adverse event is any untoward medical occurrence or effect that at any dose: • results in death • is life threatening (at the time of the event) • requires hospitalization or prolongation of existing patients’ hospitalization • results in persistent or significant disability or incapacity Note : In this study, admission for diagnosis or treatment of recurrences are not considered a SAE Recording of SAEs All SAEs must be reported initially in Castor EDC . The PI must sign the completed SAE report electronically in Castor EDC as soon as possible but no later than one working day from the time the local investigator has first knowledge of th e SAE. Castor EDC will automatically send a notification to the central study coordinator when the SAE report has been create d. The central Ethics Committee of UZA will inform the Medical Ethics Committee(s) of the participating centers."
40,page_40,"Protocol Number: v. 3.0 Date: 11 August 2020 41 The (S)AE report m ust be updated after initial submission in Castor EDC as soon as final data related to the (S)AE is available. (Suspected) Unexpected (Serious) A dverse Reactions Since the LEAD -IN FOLICOLOR Trial is a prospective intervent ional study in which there is no investigational product , (S)U(S)AR reporting does not apply . Annual report The sponsor will submit once a yea r throughout the clinical trial an annual report to the central ethical committee of the UZA for distribution to all ethical advisory boards of participating hospitals. This annual report consists of: • A status update of the trial, including but not limited to the following: date of EC approval, date of inclusion of first study patient, total number of patients included, total number of patients who discontinued their participation (end of study); • An aggregated summary table of all serious adverse events, ordered by organ system ."
41,page_41,"Protocol Number: v. 3.0 Date: 11 August 2020 42 10 ADMINISTRATION PROCEDURES AND PUBLI CATION Regulatory Approval As required by local regulations, the sponsor will ensure all legal regulatory aspects are covered, and obtain approval of the appropriate regulatory bodies, prior to study initiation in regions where an appro val is required. Publication Policy The sponsor encourages acknowledgement of all individuals/organizations involved in the funding or conduct of the study, including medical writers or statisticians subject to the consent of each individual and entity con cerned, including acknowledgement of the sponsor. The results of this study may be published or communicated to scientific meetings by the investigators involved in the study. Contractual and Financial Details The Investigator (and/or, as appropriate, the hospital administrative representative) and the sponsor will sign a clinical study agreement prior to the start of the study, outlining overall sponsor and investigator responsibilities in relation to the study. Insurance, Indemnity and Compensation The sponsor has a liability insurance which will be annually renewed."
42,page_42,"Protocol Number: v. 3.0 Date: 11 August 2020 43 11 MONITORING Monitoring in Belgium will be done according to ICH-GCP E6 Guideline and by medically qualified personnel . The LEAD -IN FOLICOLOR Trial is classified as a low -risk trial and therefore minimal monitoring is required. The purposes of trial monitoring are to verify that:  The rights and well -being o f human subjects are protected.  The reported trial data are accurate, complete, and ve rifiable from source documents.  The conduct of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with the applicable regulatory requirement(s). Objective of on -site monitoring:  To identify procedural errors in the execution of the research Central monitoring:  Detection of missing, late and inaccurate research Source Data Verification:  Monitoring will be performed accord ing to the Data Monitoring Plan, which can be consulted in the Trial Master File that is saved in the Antwerp University Hospital. Overview o f data collection Demographics - Sex - Age - Language - Race - Date of birth - Weight Inclusion criteria - Cfr. 5.1 Exclusion criteria - Cfr. 5.2 Baseline - Location of tumor - Relevant medical history - Recent blood transfusion Follow -up - Chemotherapy information: name, dose, (date of) administration - Imaging: imaging technique, date of imaging - Report of target lesions: sum of diameters, general evolution - Report of non -target lesions: sum of diameters, general evolution - Assessment of new lesions: type, location - CEA: level, date Adverse Events - According to the NCI-CTCAE version 5.0, published November 27, 2017 - System organ code - AE term"
43,page_43,"Protocol Number: v. 3.0 Date: 11 August 2020 44 - Start date - Outcome - End date - Severity - Relation to therapy - Relation to liquid biopsy sampling - Action with (chemo)therapy - Treatment of AE (incl. medications) - Unexpected AE Serious Adverse Events - Patient initials - System organ code - SAE term - Description of the SAE incident - Onset period & date - Severity - Category - Outcome - Date of recovery - Relation to therapy - Relation to liquid biopsy sampling - Action with (chemo)therapy - Treatment of SAE (incl. surgery, medications) - Relevant medical history - Contact person (name, e -mail address, telephone number) Death - Date of death - Autopsy (report) - Cause of death End of Study - Last date in study - ECOG - Reason for end of study - Date of metastasectomy Questionnaire - Dutch: cfr. Appendix 15.2 & 15.3 - French: cfr. Appendix 15.4 & 15.5 Liquid Biopsy Sampling - Confirmation LB collection - Date of collection - Reason for missing LBs - Confirmation shipment of LBs Mandatory data Castor EDC visualizes which data is mandatory, and which data can be entered without obligation. Data entry & monitoring guidelines The guidelines for data entry and monitoring in Castor EDC can be consulted in the Data Entry Manual."
44,page_44,"Protocol Number: v. 3.0 Date: 11 August 2020 45 12 STUDY ADMINISTR ATION Coordinating S tudy Team The Coordinating Study Team will govern the conduct of the study. The Coordinating Study Team will be composed of the Chief Investigator, the central study coordinator of UZA, representatives of CMG Antwerp, representatives of the UZA Biobank, and representatives of Amgen. 13 CONFLICT OF INTEREST POLICY The independence of this study from any actual or perceived influence, such as by the pharmaceutical industry, is critical. Therefore , any actual conflict of interest of persons who have a role in the design, conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore, persons who have a perceived conflict of interest will be required to have such conflicts managed in a way th at is appropriate to their participation in the trial."
45,page_45,"Protocol Number: v. 3.0 Date: 11 August 2020 46 14 REFERENCES 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394 -424. 2. Kindler HL, Shulman KL. Metastatic colorectal cancer. Current treatment options in oncology. 2001;2(6):459 -71. 3. McLeod HL, McKay JA, Collie -Duguid ES, Cassidy J. Therapeutic opportunities from tu mour biology in metastatic colon cancer. European journal of cancer (Oxford, England : 1990). 2000;36(13 Spec No):1706 -12. 4. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. Journal of clinical oncology : official journal of the Ameri can Society of Clinical Oncology. 2004;22(7):1201 -8. 5. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of K RAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Bri tish journal of cancer. 2007;96(8):1166 -9. 6. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild - type K RAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(10):1626 -34. 7. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, et al. Association of k -RAS, b-raf, and p53 status with the treatment effect of bevacizumab. Journal of the National Cancer Institute. 2005;97(13):981 -9. 8. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten RAS mutations in patients with colorectal cancer: the ' RASCAL II' study. British journal of cancer. 2001;85(5):692 -6. 9. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab -FOLFOX4 treatment and RAS mutations in colorectal cancer. The New England journal of medicine. 2013;369(11):1023 -34. 10. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild -type K RAS exon 2 metas tatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(21):2240 -7. 11. Abad A, Massuti B, Gravalos C, Escudero P, Guillen C, Manzano JL, et al. Phase II trial of panitumumab plus FOLFO X4 or FOLFIRI in subjects with K RAS wild-type colorectal cancer and liver -limited disease: The PLANET study. Journal of Clinical Oncology. 2014;32(15_suppl):3560 -. 12. Karthaus M, Hofheinz RD, Mineur L, Letocha H, Greil R, Thaler J, et al. Impact of tumour RAS/BRAF status in a first -line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. British journal of cancer. 2016;115(10):1215 -22. 13. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensu s guidelines for the management of patients with metastatic colorectal"
46,page_46,"Protocol Number: v. 3.0 Date: 11 August 2020 47 cancer. Annals of Oncology. 2016;27(8):1386 -422. 14. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer -genetics in the blood. Nat Rev Clin Oncol. 20 13;10(8):472 -84. 15. Goebel G, Zitt M, Zitt M, Muller HM. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers. 2005;21(3):105 -20. 16. Garlan F, Laurent -Puig P, Sefrioui D, Siauve N, Didelot A, Sarafan -Vasseur N, et al. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). Clinical cancer research : an official journal of the American Association for Cancer Research. 2017;23(18):5416 -25. 17. Orntoft MB, Nielsen HJ, Orntoft TF, Andersen CL, Danish Study Group on Early Detection of Colorectal C. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case -control study. BMC Cancer. 2015;15:819. 18. Cuyle PJ, Prenen H. Current and future biomarkers in the treatment of colorectal cancer. Acta clinica Belgica. 2017;72(2):103 -15. 19. Osumi H, Shinozaki E, Yamaguchi K, Zembutsu H. Clinical utility of circulating tumor DNA for colorectal cancer. Cancer science. 2019;110(4):1148 -55. 20. Toth K, Bartak BK, Tulassay Z, Molnar B. Circulating cell -free nucleic acids as biomarkers in colorectal cancer screening and diagnosis. Expert review of molecular diagnostics. 2016;16(2):239 -52. 21. Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, et al. Combined circulating tumor DNA and protein biomarker -based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A. 2017;114(38): 10202 -7. 22. Boeckx N, Op de Beeck K, Beyens M, Deschoolmeester V, Hermans C, De Clercq P, et al. Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow -up of Metastatic Colorectal Cancer Patients. Clin Colorectal Cancer. 2018;17 (2):e369 -e79. 23. Roperch JP, Incitti R, Forbin S, Bard F, Mansour H, Mesli F, et al. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood -based diagnosis of colorectal cancer. BMC cancer. 2013;13:566. 24. Baylin SB, Jones PA. A deca de of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726 -34. 25. Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, Le Corre D, et al. A Study of Hypermethylated Circulating Tumor DNA as a Univer sal Colorectal Cancer Biomarker. Clin Chem. 2016;62(8):1129 -39. 26. Danese E, Minicozzi AM, Benati M, Montagnana M, Paviati E, Salvagno GL, et al. Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients wit h colorectal cancer. PloS one. 2015;10(5):e0126417. 27. Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 2011;9:133. 28. Church TR, Wande ll M, Lofton -Day C, Mongin SJ, Burger M, Payne SR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63(2):317 -25. 29. Lange CP, Campan M, Hinoue T, Schmitz RF, van der Meulen -de Jong AE, Slingerland H, et al. Genome -scale discovery of DNA -methylation biomarkers for blood - based detection of colorectal cancer. PloS one. 2012;7(11):e50266."
47,page_47,"Protocol Number: v. 3.0 Date: 11 August 2020 48 30. Young GP, Pedersen SK, Mansfield S, Murray DH, Baker RT, Rabbitt P, et al. A cross -sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor - derived DNA with CEA for detection of recurrent colorectal cancer. Cancer Med. 2016;5(10):2763 -72. 31. Barault L, Amatu A, Siravegna G, Ponzetti A, Moran S, Cassingena A, et al. Discovery of methy lated circulating DNA biomarkers for comprehensive non -invasive monitoring of treatment response in metastatic colorectal cancer. Gut. 2018;67(11):1995 - 2005. 32. Dong Y, Zhao H, Li H, Li X, Yang S. DNA methylation as an early diagnostic marker of cancer (R eview). Biomed Rep. 2014;2(3):326 -30. 33. Lam K, Pan K, Linnekamp JF, Medema JP, Kandimalla R. DNA methylation based biomarkers in colorectal cancer: A systematic review. Biochim Biophys Acta. 2016;1866(1):106 -20. 34. McQuade RM, Stojanovska V, Bornstein J C, Nurgali K. Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches. Current medicinal chemistry. 2017;24(15):1537 -57. 35. Eisenhauer EA, The RASse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteri a in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England : 1990). 2009;45(2):228 -47. 36. Thomsen CB, Hansen TF, Andersen RF, Lindebjerg J, Jensen LH, Jakobsen A. Monitoring the effect of first line treatment i n RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma. Journal of experimental & clinical cancer research : CR. 2018;37(1):55. 37. Hofheinz R, Mineur L, Greil R, Kohne C, Letocha H, Thaler J, et al. Panitumumab (pmab) with FOLFIRI as first -line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Resections and curative surgery in a phase II single arm, multicenter study (20060314). Journal of Clinical Oncology. 2010;28(15_suppl):3545 -. 38. Symonds LK, Cohen SA. Use of perioperative chemotherapy in colorectal cancer metastatic to the liver. Gastroenterology Report. 2019;7(5):301 -11. 39. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first - line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(7):1346 -55."
48,page_48,Protocol Number: v. 3.0 Date: 11 August 2020 49 15 APPENDIX Follow -Up Scheme
49,page_49,"Protocol Number: v. 3.0 Date: 11 August 2020 50 Questionnaire 1 (Dutch version) Mee tmoment vragenlijst: start eerstelijnstherapie Mijn geboortedatum (ter controle): __ __ / __ __ / __ __ __ __ (Dag/Maand/ Jaar) Datum van vandaag: __ __ / __ __ / __ __ __ __ (Dag/Maand/ Jaar) Mijn geslacht:  Man  Vrouw Volgende pagina, a.u.b. EORTC QLQ -C30 – Kwaliteit van leven Wilt u alle vragen zelf beantwoorden door het getal te omcirkelen dat het meest op u van toepassing is? Er zijn geen “juiste” of “onjuiste” antwoorden. De informatie die u geeft zal strikt vertrouwelijk worden behandeld. Helemaal niet Een beetje Nogal Heel erg 1. Heeft u moeite met het doen van inspannende activiteiten zoals het dragen van een zware boodschappentas of een koffer? 1 2 3 4 2. Heeft u moeite met het maken van een lange wandeling? 1 2 3 4 3. Heeft u moeite met het maken van een korte wandeling buitenshuis? 1 2 3 4 4. Moet u overdag in bed of in een stoel blijven? 1 2 3 4 5. Heeft u hulp nodig met eten, aankleden, u zelf wassen of naar het toilet gaan? 1 2 3 4 Gedurende de afgelopen week: Helemaal niet Een beetje Nogal Heel erg 6. Was u beperkt bij het doen van uw werk of andere dagelijkse bezigheden? 1 2 3 4 7. Was u beperkt in het uitoefenen van uw hobby’ s of bij andere bezigheden die u in uw vrije tijd doet? 1 2 3 4 8. Was u kortademig? 1 2 3 4 9. Heeft u pijn gehad? 1 2 3 4 10. Had u behoefte om te rusten? 1 2 3 4"
50,page_50,"Protocol Number: v. 3.0 Date: 11 August 2020 51 Volgende pagina, a.u.b. 11. Heeft u moeite met slapen gehad? 1 2 3 4 12. Heeft u zich slap gevoeld? 1 2 3 4 13. Heeft u gebrek aan eetlust gehad? 1 2 3 4 14. Heeft u zich misselijk gevoeld? 1 2 3 4 Gedurende de afgelopen week: Helemaal niet Een beetje Nogal Heel erg 15. Heeft u overgegeven? 1 2 3 4 16. Had u last van obstipatie? (Was u verstopt?) 1 2 3 4 17. Had u diarree? 1 2 3 4 18. Was u moe? 1 2 3 4 19. Heeft pijn u gehinderd in uw dagelijkse bezigheden? 1 2 3 4 20. Heeft u moeite gehad met het concentreren op dingen, zoals een krant lezen of televisie kijken? 1 2 3 4 21. Voelde u zich gespannen? 1 2 3 4 22. Maakte u zich zorgen? 1 2 3 4 23. Voelde u zich prikkelbaar? 1 2 3 4 24. Voelde u zich neerslachtig? 1 2 3 4 25. Heeft u moeite gehad met het herinneren van dingen? 1 2 3 4 26. Heeft uw lichamelijke toestand of medische behandeling uw familieleven in de weg gestaan? 1 2 3 4 27. Heeft uw lichamelijke toestand of medische behandeling u belemmerd in uw sociale bezigheden? 1 2 3 4 28. Heeft uw lichamelijke toestand of medische behandeling financiële moeilijkheden met zich meegebracht? 1 2 3 4"
51,page_51,"Protocol Number: v. 3.0 Date: 11 August 2020 52 Volgende pagina, a.u.b. Wilt u voor de volgende vragen het getal tussen 1 en 7 omcirkelen dat het meest op u van toepassing is: 29. Hoe zou u uw algehele gezondheid gedurende de afgelopen week beoordelen? 1 2 3 4 5 6 7 Erg slecht Uitstekend 30. Hoe zou u uw algehele “kwaliteit van het leven” gedurende de afgelopen week beoordelen? 1 2 3 4 5 6 7 Erg slecht Uitstekend © Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 EORTC QLQ -CR29 – Ziekte -specifieke levenskwaliteit Soms zeggen patiënten dat ze de volgende klachten of problemen hebben. Wilt u aangeven in welke mate u deze klachten of problemen gedurende de afgelopen week heeft ervaren? Wilt u de vragen beantwoorden door het vakje aan te kruisen dat het meest op u van toepassing is? Gedurende de afgelopen week: Helemaal niet Een beetje Nogal Heel erg 31. Heeft u overdag meer dan gewoonlijk geplast? 1 2 3 4 32. Heeft u ’s nachts meer dan gewoonlijk geplast? 1 2 3 4 33. Heeft u ongewild urine verloren? 1 2 3 4 34. Heeft u pijn gehad bij het plassen? 1 2 3 4 35. Heeft u buikpijn gehad? 1 2 3 4 36. Heeft u pijn gehad in uw zitvlak of bij uw anus? 1 2 3 4 37. Heeft u een opgeblazen gevoel gehad in uw buik? 1 2 3 4 38. Heeft u bloed in uw ontlasting gehad? 1 2 3 4"
52,page_52,"Protocol Number: v. 3.0 Date: 11 August 2020 53 Volgende pagina, a.u.b. Gedurende de afgelopen week: Helemaal niet Een beetje Nogal Heel erg 39. Heeft u slijm in uw ontlasting gehad? 1 2 3 4 40. Heeft u een droge mond gehad? 1 2 3 4 41. Heeft u haaruitval gehad ten gevolge van uw behandeling? 1 2 3 4 42. Heeft u problemen met uw smaak gehad? 1 2 3 4 43. Heeft u zich zorgen gemaakt over uw gezondheid in de toekomst? 1 2 3 4 44. Heeft u zich zorgen gemaakt over uw gewicht(sverlies)? 1 2 3 4 45. Voelde u zich lichamelijk minder aantrekkelijk ten gevolge van uw ziekte of behandeling? 1 2 3 4 46. Voelde u zich minder vrouwelijk/mannelijk ten gevolge van uw ziekte of behandeling? 1 2 3 4 47. Was u ontevreden met uw lichaam? 1 2 3 4 48. Heeft u een stoma? (dunnedarm -stoma of dikkedarm -stoma)  Ja  Nee Beantwoord deze vragen (vraag 49 tot en met 55) ALLEEN ALS U EEN STOMA HEEFT, zo niet, ga dan naar vraag 56. Gedurende de afgelopen week: Helemaal niet Een beetje Nogal Heel erg 49. Heeft u last gehad van het ongewild vrijkomen van gas (winderigheid) uit uw stoma? 1 2 3 4 50. Was er lekkage van ontlasting uit uw stomazakje? 1 2 3 4 51. Heeft u een pijnlijke huid gehad rond uw stoma? 1 2 3 4 52. Heeft u overdag vaak het stomazakje moeten vervangen? 1 2 3 4 53. Heeft u ’s nachts vaak het stomazakje moeten vervangen? 1 2 3 4 54. Voelde u zich ongemakkelijk/opgelaten door uw stoma? 1 2 3 4 55. Heeft u problemen gehad met de verzorging van uw stoma? 1 2 3 4"
53,page_53,Protocol Number: v. 3.0 Date: 11 August 2020 54 Gedurende de afgelopen 4 weken: (alleen voor MANNEN) Helemaal niet Een beetje Nogal Heel erg 62. In hoeverre had u zin in seks? 1 2 3 4 63. Indien u seksueel actief was (met of zonder geslachtsgemeenschap): had u moeite met het stijf worden of blijven van uw penis? 1 2 3 4 Gedurende de afgelopen 4 weken: (alleen voor VROUWEN) Helemaal niet Een beetje Nogal Heel erg 64. In hoeverre had u zin in seks? 1 2 3 4 65. Indien u geslachtsgemeenschap heeft gehad: had u pijn of ongemak tijdens de gemeenschap? 1 2 3 4 © QLQ -CR29 Copyright 2006 EORTC Quality of Life Group. All rights reserved. Version 2.1 Bedankt voor het invullen van deze vragenlijst! Het FOLICOLOR Lead -In onderzoeksteam Beantwoord deze vragen (vraag 56 tot en met 61) ALLEEN ALS U GEEN STOMA HEEFT. Gedurende de afgelopen week: Helemaal niet Een beetje Nogal Heel erg 56. Heeft u last gehad van het ongewild vrijkomen van gas (winderigheid)? 1 2 3 4 57. Heeft u ongewild ontlasting verloren? 1 2 3 4 58. Heeft u een pijnlijke huid gehad rondom uw anus? 1 2 3 4 59. Heeft u overdag vaak ontlasting gehad? 1 2 3 4 60. Heeft u ’s nachts vaak ontlasting gehad? 1 2 3 4 61. Voelde u zich ongemakkelijk/opgelaten door uw ontlastingspatroon? 1 2 3 4
54,page_54,"Protocol Number: v. 3.0 Date: 11 August 2020 55 Questionnaire 1 (French version) Questionnaire à remplir après 9 mois de suivi ou fin d’étude prématuré Ma date de naissance (pour vérification): __ __ / __ __ / __ __ __ __ (Jour/Mois/ Année) Date d’aujourd’hui: __ __ / __ __ / __ __ __ __ (Jour/Mois/ Année) Sexe:  Masculin  Féminin (marquer d’une croix la bonne case) EORTC QLQ -C30 – Qualité de vie Répondez vous -même à toutes les questions en entourant le chiffre qui correspond le mieux à votre situation. Il n’y a pas de “bonne” ou de “mauvaise” réponse. Ces informations sont strictement confidentielles. Pas du tout Un peu Assez Beaucoup 66. Avez -vous des difficultés à faire certains efforts physiques pénibles comme porter un sac à provisions chargé ou une valise? 1 2 3 4 67. Avez -vous des difficultés à faire une longue promenade ? 1 2 3 4 68. Avez -vous des difficultés à faire un petit tour dehors? 1 2 3 4 69. Etes -vous obligée de rester au lit ou dans un fauteuil pendant la journée? 1 2 3 4 70. Avez -vous besoin d’aide pour manger, vous habiller, faire votre toilette ou aller aux toilettes? 1 2 3 4 Au cours de la semaine passée: Pas du tout Un peu Assez Beaucoup 71. Avez - vous été gênée pour faire votre travail ou vos activités de tous les jours? 1 2 3 4 72. Avez -vous été gênée dans vos activités de loisirs? 1 2 3 4 73. Avez -vous eu le souffle court? 1 2 3 4 74. Avez -vous ressenti de la douleur? 1 2 3 4 75. Avez -vous eu besoin de repos? 1 2 3 4"
55,page_55,"Protocol Number: v. 3.0 Date: 11 August 2020 56 Au cours de la semaine passée: Pas du tout Un peu Assez Beaucoup 76. Avez -vous eu des difficultés pour dormir? 1 2 3 4 77. Vous êtes -vous sentie faible? 1 2 3 4 78. Avez -vous manqué d’appétit? 1 2 3 4 79. Avez -vous eu des nausées (mal au coeur)? 1 2 3 4 80. Avez -vous vomi? 1 2 3 4 81. Avez -vous été constipée? 1 2 3 4 82. Avez -vous eu de la diarrhée? 1 2 3 4 83. Etiez -vous fatiguée? 1 2 3 4 84. Des douleurs ont -elles perturbé vos activités quotidiennes? 1 2 3 4 85. Avez -vous eu des difficultés à vous concentrer sur certaines choses par exemple pour lire le journal ou regarder la télévision? 1 2 3 4 86. Vous êtes -vous sentie tendue? 1 2 3 4 87. Vous êtes -vous fait du souci? 1 2 3 4 88. Vous êtes -vous sentie irritable? 1 2 3 4 89. Vous êtes -vous sentie déprimée? 1 2 3 4 90. Avez -vous eu des difficultés pour vous souvenir de certaines choses? 1 2 3 4 91. Votre état physique ou votre traitement médical vous ont -ils gênée dans votre vie familiale ? 1 2 3 4 92. Votre état physique ou votre traitement médical vous ont -ils gênée dans vos activités sociales (par exemple, sortir avec des amis, aller au cinéma…)? 1 2 3 4 93. Votre état physique ou votre traitement médical vous ont -ils causé des problèmes financiers? 1 2 3 4 Voir page suivante S.V.P."
56,page_56,"Protocol Number: v. 3.0 Date: 11 August 2020 57 Veuillez répondre en entourant le chiffre entre 1 et 7 qui s’applique le mieux à votre situation: 94. Comment évalueriez -vous votre état de santé au cours de la semaine passée? 1 2 3 4 5 6 7 Très mauvais Excellent 95. Comment évalueriez -vous l’ensemble de votre qualité de vie au cours de la semaine passée? 1 2 3 4 5 6 7 Très mauvaise Excellente © Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 EORTC QLQ -CR29 – Qualité de vie spécifique à la maladie Les patients rapportent parfois les symptômes ou problèmes suivants. Pourriez -vous indiquer, s’il vous plaît, si, durant la semaine passée, vous avez été affecté(e) par l’un de ces symptômes ou problèmes. Entourez, s’il vous plaît, le chiffre qui correspond le mieux à votre situation. Au cours de la semaine passée: Pas du tout Un peu Assez Beaucoup 96. Avez -vous fréquemment uriné dans la journée? 1 2 3 4 97. Avez -vous fréquemment uriné pendant la nuit? 1 2 3 4 98. Avez -vous eu des fuites urinaires? 1 2 3 4 99. Avez -vous eu des douleurs en urinant? 1 2 3 4 100. Avez -vous eu mal au ventre? 1 2 3 4 101. Avez -vous ressenti des douleurs au niveau de la région anale? 1 2 3 4 102. Vous êtes -vous senti(e) ballonné(e)? 1 2 3 4 103. Avez -vous vu du sang dans vos selles? 1 2 3 4 Voir page suivante S.V.P."
57,page_57,"Protocol Number: v. 3.0 Date: 11 August 2020 58 Au cours de la semaine passée: Pas du tout Un peu Assez Beaucoup 104. Avez -vous constaté des glaires dans vos selles? 1 2 3 4 105. Avez -vous eu la bouche sèche? 1 2 3 4 106. Avez -vous perdu des cheveux du fait de votre traitement? 1 2 3 4 107. Les aliments avaient -ils un goût inhabituel ? 1 2 3 4 108. Vous êtes -vous inquiété(e) de votre santé pour l’avenir? 1 2 3 4 109. Vous êtes -vous inquiété(e) de votre poids? 1 2 3 4 110. Vous êtes -vous senti(e) moins attirant(e) du fait de votre maladie ou de votre traitement ? 1 2 3 4 111. Vous êtes -vous senti(e) moins femme/homme du fait de votre maladie ou de votre traitement ? 1 2 3 4 112. Votre corps vous a -t-il déplu? 1 2 3 4 113. Avez -vous un anus artificiel (stomie)?  Oui  Non Ne répondez aux questions 49 – 55 que SI VOUS AVEZ UN ANUS ARTIFICIEL. Dans le cas contraire, passez directement à la série de questions 58 - 63. Au cours de la semaine passée: Pas du tout Un peu Assez Beaucoup 114. Avez -vous eu des fuites de gaz par votre anus artificiel (stomie)? 1 2 3 4 115. Avez -vous eu des fuites de matières fécales en dehors de votre poche de stomie? 1 2 3 4 116. La peau entourant votre anus artificiel (stomie) vous a -t-elle fait souffrir? 1 2 3 4 117. Avez -vous dû souvent changer votre poche de stomie au cours de la journée? 1 2 3 4 118. Avez -vous dû souvent changer votre poche de stomie au cours de la nuit? 1 2 3 4 119. Vous êtes -vous senti(e) gêné(e) à cause de votre poche? 1 2 3 4 120. Les soins de votre poche de stomie vous ont-ils posé des problèmes? 1 2 3 4"
58,page_58,Protocol Number: v. 3.0 Date: 11 August 2020 59 Ne répondez aux questions 56 – 61 que SI VOUS N’AVEZ PAS D’ANUS ARTIFICIEL. Au cours de la semaine passée: Pas du tout Un peu Assez Beaucoup 121. Avez -vous eu des fuites de gaz involontaires par l’anus? 1 2 3 4 122. Avez -vous eu des fuites de matières fécales par l’anus? 1 2 3 4 123. La peau entourant votre anus vous a -t-elle fait souffrir? 1 2 3 4 124. Avez -vous dû fréquemment aller à la selle au cours de la journée? 1 2 3 4 125. Avez -vous dû fréquemment aller à la selle au cours de la nuit? 1 2 3 4 126. Vous êtes -vous senti(e) gêné(e) lorsque vous alliez à la selle? 1 2 3 4 Au cours des 4 dernières semaines: Pour les HOMMES uniquement: Pas du tout Un peu Assez Beaucoup 127. Dans quelle mesure vous êtes -vous intéressé à la sexualité? 1 2 3 4 128. Avez -vous eu des difficultés à avoir une érection ou à rester en érection? 1 2 3 4 Au cours des 4 dernières semaines: Pour les FEMMES uniquement: Pas du tout Un peu Assez Beaucoup 129. Dans quelle mesure vous êtes -vous intéressée à la sexualité? 1 2 3 4 130. Avez -vous ressenti des douleurs ou une gêne lors des rapports sexuels? 1 2 3 4 © QLQ -CR29 Copyright 2006 EORTC Quality of Life Group. All rights reserved. Version 2.1 Merci d’avoir rempli ce questionnaire ! L’équipe de recherche de LEAD -IN FOLICOLOR Trial
59,page_59,"Protocol Number: v. 3.0 Date: 11 August 2020 60 Questionnaire 2 (Dutch version) In te vullen na 9 maanden follow -up of bij vroegtijdig beëindigen van de studie Mijn geboortedatum (ter controle): __ __ / __ __ / __ __ __ __ (Dag/Maand/ Jaar) Dag van vandaag: __ __ / __ __ / __ __ __ __ (Dag/Maand/ Jaar) Mijn geslacht:  Man  Vrouw EORTC QLQ -C30 – Kwaliteit van leven Wilt u alle vragen zelf beantwoorden door het getal te omcirkelen dat het meest op u van toepassing is? Er zijn geen “juiste” of “onjuiste” antwoorden. De informatie die u geeft zal strikt vertrouwelijk worden behandeld. Helemaal niet Een beetje Nogal Heel erg 131. Heeft u moeite met het doen van inspannende activiteiten zoals het dragen van een zware boodschappentas of een koffer? 1 2 3 4 132. Heeft u moeite met het maken van een lange wandeling? 1 2 3 4 133. Heeft u moeite met het maken van een korte wandeling buitenshuis? 1 2 3 4 134. Moet u overdag in bed of in een stoel blijven? 1 2 3 4 135. Heeft u hulp nodig met eten, aankleden, u zelf wassen of naar het toilet gaan? 1 2 3 4 Gedurende de afgelopen week: Helemaal niet Een beetje Nogal Heel erg 136. Was u beperkt bij het doen van uw werk of andere dagelijkse bezigheden? 1 2 3 4 137. Was u beperkt in het uitoefenen van uw hobbies of bij andere bezigheden die u in uw vrije tijd doet? 1 2 3 4 138. Was u kortademig? 1 2 3 4 139. Heeft u pijn gehad? 1 2 3 4 140. Had u behoefte om te rusten? 1 2 3 4"
60,page_60,"Protocol Number: v. 3.0 Date: 11 August 2020 61 141. Heeft u moeite met slapen gehad? 1 2 3 4 142. Heeft u zich slap gevoeld? 1 2 3 4 143. Heeft u gebrek aan eetlust gehad? 1 2 3 4 144. Heeft u zich misselijk gevoeld? 1 2 3 4 Gedurende de afgelopen week: Helemaal niet Een beetje Nogal Heel erg 145. Heeft u overgegeven? 1 2 3 4 146. Had u last van obstipatie? (Was u verstopt?) 1 2 3 4 147. Had u diarree? 1 2 3 4 148. Was u moe? 1 2 3 4 149. Heeft pijn u gehinderd in uw dagelijkse bezigheden? 1 2 3 4 150. Heeft u moeite gehad met het concentreren op dingen, zoals een krant lezen of televisie kijken? 1 2 3 4 151. Voelde u zich gespannen? 1 2 3 4 152. Maakte u zich zorgen? 1 2 3 4 153. Voelde u zich prikkelbaar? 1 2 3 4 154. Voelde u zich neerslachtig? 1 2 3 4 155. Heeft u moeite gehad met het herinneren van dingen? 1 2 3 4 156. Heeft uw lichamelijke toestand of medische behandeling uw familieleven in de weg gestaan? 1 2 3 4 157. Heeft uw lichamelijke toestand of medische behandeling u belemmerd in uw sociale bezigheden? 1 2 3 4 158. Heeft uw lichamelijke toestand of medische behandeling financiële moeilijkheden met zich meegebracht? 1 2 3 4 Volgende pagina, a.u.b."
61,page_61,"Protocol Number: v. 3.0 Date: 11 August 2020 62 Wilt u voor de volgende vragen het getal tussen 1 en 7 omcirkelen dat het meest op u van toepassing is: 159. Hoe zou u uw algehele gezondheid gedurende de afgelopen week beoordelen? 1 2 3 4 5 6 7 Erg slecht Uitstekend 160. Hoe zou u uw algehele “ kwaliteit van het leven” gedurende de afgelopen week beoordelen? 1 2 3 4 5 6 7 Erg slecht Uitstekend EORTC QLQ -CR29 – Ziekte -specifieke levenskwaliteit Soms zeggen patiënten dat ze de volgende klachten of problemen hebben. Wilt u aangeven in welke mate u deze klachten of problemen gedurende de afgelopen week heeft ervaren? Wilt u de vragen beantwoorden door het vakje aan te kruisen dat het meest op u van toepassing is? Gedurende de afgelopen week: Helemaal niet Een beetje Nogal Heel erg 161. Heeft u overdag meer dan gewoonlijk geplast? 1 2 3 4 162. Heeft u ’s nachts meer dan gewoonlijk geplast? 1 2 3 4 163. Heeft u ongewild urine verloren? 1 2 3 4 164. Heeft u pijn gehad bij het plassen? 1 2 3 4 165. Heeft u buikpijn gehad? 1 2 3 4 166. Heeft u pijn gehad in uw zitvlak of bij uw anus? 1 2 3 4 167. Heeft u een opgeblazen gevoel gehad in uw buik? 1 2 3 4 168. Heeft u bloed in uw ontlasting gehad? 1 2 3 4 Volgende pagina, a.u.b."
62,page_62,"Protocol Number: v. 3.0 Date: 11 August 2020 63 Gedurende de afgelopen week: Helemaal niet Een beetje Nogal Heel erg 169. Heeft u slijm in uw ontlasting gehad? 1 2 3 4 170. Heeft u een droge mond gehad? 1 2 3 4 171. Heeft u haaruitval gehad ten gevolge van uw behandeling? 1 2 3 4 172. Heeft u problemen met uw smaak gehad? 1 2 3 4 173. Heeft u zich zorgen gemaakt over uw gezondheid in de toekomst? 1 2 3 4 174. Heeft u zich zorgen gemaakt over uw gewicht(sverlies)? 1 2 3 4 175. Voelde u zich lichamelijk minder aantrekkelijk ten gevolge van uw ziekte of behandeling? 1 2 3 4 176. Voelde u zich minder vrouwelijk/mannelijk ten gevolge van uw ziekte of behandeling? 1 2 3 4 177. Was u ontevreden met uw lichaam? 1 2 3 4 178. Heeft u een stoma? (dunnedarm -stoma of dikkedarm -stoma)  Ja  Nee Beantwoord deze vragen (vraag 49 tot en met 55) ALLEEN ALS U EEN STOMA HEEFT, zo niet, ga dan naar vraag 58. Gedurende de afgelopen week: Helemaal niet Een beetje Nogal Heel erg 179. Heeft u last gehad van het ongewild vrijkomen van gas (winderigheid) uit uw stoma? 1 2 3 4 180. Was er lekkage van ontlasting uit uw stomazakje? 1 2 3 4 181. Heeft u een pijnlijke huid gehad rond uw stoma? 1 2 3 4 182. Heeft u overdag vaak het stomazakje moeten vervangen? 1 2 3 4 183. Heeft u ’s nachts vaak het stomazakje moeten vervangen? 1 2 3 4 184. Voelde u zich ongemakkelijk/opgelaten door uw stoma? 1 2 3 4 185. Heeft u problemen gehad met de verzorging van uw stoma? 1 2 3 4"
63,page_63,"Protocol Number: v. 3.0 Date: 11 August 2020 64 Beantwoord deze vragen (vraag 56 tot en met 61) ALLEEN ALS U GEEN STOMA HEEFT. Gedurende de afgelopen week: Helemaal niet Een beetje Nogal Heel erg 186. Heeft u last gehad van het ongewild vrijkomen van gas (winderigheid)? 1 2 3 4 187. Heeft u ongewild ontlasting verloren? 1 2 3 4 188. Heeft u een pijnlijke huid gehad rondom uw anus? 1 2 3 4 189. Heeft u overdag vaak ontlasting gehad? 1 2 3 4 190. Heeft u ’s nachts vaak ontlasting gehad? 1 2 3 4 191. Voelde u zich ongemakkelijk/opgelaten door uw ontlastingspatroon? 1 2 3 4 Gedurende de afgelopen 4 weken: Alleen voor MANNEN: Helemaal niet Een beetje Nogal Heel erg 192. In hoeverre had u zin in seks? 1 2 3 4 193. Indien u seksueel actief was (met of zonder geslachtsgemeenschap): had u moeite met het stijf worden of blijven van uw penis? 1 2 3 4 Gedurende de afgelopen 4 weken: Alleen voor VROUWEN: Helemaal niet Een beetje Nogal Heel erg 194. In hoeverre had u zin in seks? 1 2 3 4 195. Indien u geslachtsgemeenschap heeft gehad: had u pijn of ongemak tijdens de gemeenschap? 1 2 3 4 Volgende pagina, a.u.b."
64,page_64,"Protocol Number: v. 3.0 Date: 11 August 2020 65 Vragenlijst m.b.t. ervaring van patiënten Beste patiënt, Uw mening telt. Om de zorg voor patiënten met darmkanker te verbeteren, doen we onderzoek naar opvolgingsmethodes voor darmkanker. In deze korte vragenlijst willen we peilen naar uw ervaring met de verschillende opvolgingsmethodes. Deze vragenlijst wordt anoniem verwerkt. Alvast bedankt voor uw deelname. Het FOLICOLOR LEAD -IN onderzoeksteam Vraag 1 Wanneer u terugdenkt aan uw ervaring tijdens de CT -scan met toediening van contrastvloeistof (via een infuus), kunt u aangeven in hoeverre u de volgende ongemakken ervaarde: Omcirkel het getal dat het meest op u van toepassing is (maximaal één antwoord mogelijk) Helemaal niet Nauwelijks In redelijke mate In hoge mate In zeer hoge mate 1. Pijn bij plaatsen van het infuus 1 2 3 4 5 2. Warm gevoel, gevoel dat je moet plassen na toediening van contrast 1 2 3 4 5 3. Onwel gevoel na toediening van contrast 1 2 3 4 5 4. Onaangename smaak na toediening van contrast 1 2 3 4 5 5. Angst in de scan 1 2 3 4 5 6. Claustrofobisch gevoel in de CT-scan 1 2 3 4 5 Volgende pagina, a.u.b."
65,page_65,"Protocol Number: v. 3.0 Date: 11 August 2020 66 Helemaal niet Nauwelijks In redelijke mate In hoge mate In zeer hoge mate 7. Gevoel van isolatie, alleen te zijn tijdens de scan 1 2 3 4 5 8. Oncomfortabele positie in de CT-scan 1 2 3 4 5 9. Ongemak ten gevolge van te lange duurtijd van de scan 1 2 3 4 5 10. Andere, namelijk: 1 2 3 4 5 …………………………………………………………………………………………………………………………………………………………… ……………………………………………………………………………………………………… …………………………………………………… …………………………………………………………………………………………………………………………………………………………… Vraag 2 Wanneer u terugdenkt aan uw ervaring tijdens de afname van de twee extra bloedtubes voor deze studie bovenop uw standaard bloedafname, kunt u aangeven in hoeverre u de volgende ongemakken ervaarde: Omcirkel het getal dat het meest op u van toepassing is (maximaal één antwoord mogelijk): Helemaal niet Nauwelijks In redelijke mate In hoge mate In zeer hoge mate 1. Angst tijdens bloedafname 1 2 3 4 5 2. Pijn tijdens bloedafname 1 2 3 4 5 3. Andere, namelijk: 1 2 3 4 5 …………………………………………………………………………………………………………………………………………………………… …………………………………………………………………………………………………………………………………………………………… Volgende pagina, a.u.b."
66,page_66,"Protocol Number: v. 3.0 Date: 11 August 2020 67 Vraag 3 Stel dat zowel de opvolging op basis van een CT -scan als de opvolging op basis van een bloedafname allebei bewezen evenwaardige en even doeltreffende opvolgingsmethoden voor patiënten met darmkanker zijn, welke van deze methoden zou dan uw voorkeur geniete n? Kruis het hokje aan van uw keuze (maximaal één antwoord mogelijk).  Opvolging van uw ziekte op basis van een CT -scan met toediening van contrastvloeistof via een infuus en dit om de 8 weken (dit is de huidige standaardzorg) ,  Opvolging van uw ziekte op basis van een bloedafname en dit om de 2 weken. Vraag 4 Stel dat zowel de opvolging op basis van een CT -scan als de opvolging op basis van een bloedafname allebei bewezen evenwaardige en even doeltreffende opvolgingsmethoden voor patiënten met darmkanker zijn, welke van deze methoden zou dan uw voorkeur genieten? Kruis het hokje aan van uw keuze (maximaal één antwoord mogelijk).  Opvolging van uw ziekte op basis van een CT -scan met toediening van contrastvloeistof via een infuu s en dit om de 8 weken (dit is de huidige standaardzorg) ,  Opvolging van uw ziekte op basis van een bloedafname en dit om de 4 weken. Vraag 5 Stel dat zowel de opvolging op basis van een CT -scan als de opvolging op basis van een bloedafname allebei bewez en evenwaardige en even doeltreffende opvolgingsmethoden voor patiënten met darmkanker zijn, welke van deze methoden zou dan uw voorkeur genieten? Kruis het hokje aan van uw keuze (maximaal één antwoord mogelijk).  Opvolging van uw ziekte op basis van een C T-scan met toediening van contrastvloeistof via een infuus en dit om de 8 weken (dit is de huidige standaardzorg) ,  Opvolging van uw ziekte op basis van een bloedafname en dit om de 8 weken. Vraag 6 Stel dat zowel de opvolging op basis van een CT -scan al s de opvolging op basis van een bloedafname allebei bewezen evenwaardige en even doeltreffende opvolgingsmethoden voor patiënten met darmkanker zijn, welke van deze methoden zou dan uw voorkeur genieten? (maximaal é én antwoord mogelijk)  Opvolging van uw ziekte op basis van een CT -scan met toediening van contrastvloeistof via een infuus, ongeacht de frequentie  ga naar vraag 7  Opvolging van uw ziekte op basis van een bloedafname, ongeacht de frequentie  ga naar vraag 8 Volgende pagina, a .u.b."
67,page_67,"Protocol Number: v. 3.0 Date: 11 August 2020 68 Vraag 7 Waarom kiest u ervoor om zich in dat geval toch te laten opvolgen aan de hand van een CT -scan met contrasttoediening? (meerdere antwoorden zijn mogelijk)  Ik ervaar minder angst voor dit onderzoek  Ik vind dat dit onderzoek minder pijnlijk is  Ik vind dit een meer aangename, meer comfortabele methode  Ik heb meer vertrouwen in deze methode  Ik vind dat ik mij dan minder moet verplaatsen naar het ziekenhuis  Ik vind dat ik dan minder tijd moet doorbrengen in het ziekenhuis  Andere: ……………………………………………… …………………………………………………………………………………………… …………………………………………………………………………………………………………………………… Vraag 8 Waarom kiest u ervoor om zich in dat geval toch te laten opvolgen aan de hand van regelmatige bloedafnames? (meerdere antwoorden zijn mogelijk)  Ik ervaar minder angst voor dit onderzoek  Ik vind dat dit onderzoek minder pijnlijk is  Ik vind dit een meer aangename, meer comfortabele methode  Ik heb meer vertrouwen in deze methode  Ik vind dat ik mij dan minder moet verplaatsen naar het ziekenhuis  Ik vind dat ik dan min der tijd moet doorbrengen in het ziekenhuis  Andere: …………………………………………………………………………………………………………………………………………… …………………………………………………………………………………………………………………………………………… …………………………………………………………………………………………………………………… Heeft u nog opmerkingen? Noteer deze hier: …………………… ……………………………………………………………………………………………………………………………… …………………………………………………………………………………………………………………………………………………… …………………………………………………………………………………………………………………………………………………… ………………………………………………………………………………………………………… Bedankt voor het invullen van deze vragenlijst! Het FOLICOLOR Lead -In onderzoeksteam"
68,page_68,"Protocol Number: v. 3.0 Date: 11 August 2020 69 Questionnaire 2 (French version) Questionnaire à remplir après 9 mois de suivi ou fin d’étude prématuré Ma date de naissance (pour vérification): __ __ / __ __ / __ __ __ __ (Jour/Mois/ Année) Date d’aujourd’hui: __ __ / __ __ / __ __ __ __ (Jour/Mois/ Année) Sexe:  Masculin  Féminin (marquer d’une croix la bonne case) EORTC QLQ -C30 – Qualité de vie Répondez vous -même à toutes les questions en entourant le chiffre qui correspond le mieux à votre situation. Il n’y a pas de “bonne” ou de “mauvaise” réponse. Ces informations sont strictement confidentielles. Pas du tout Un peu Assez Beaucoup 196. Avez -vous des difficultés à faire certains efforts physiques pénibles comme porter un sac à provisions chargé ou une valise? 1 2 3 4 197. Avez -vous des difficultés à faire une longue promenade ? 1 2 3 4 198. Avez -vous des difficultés à faire un petit tour dehors? 1 2 3 4 199. Etes -vous obligée de rester au lit ou dans un fauteuil pendant la journée? 1 2 3 4 200. Avez -vous besoin d’aide pour manger, vous habiller, faire votre toilette ou aller aux toilettes? 1 2 3 4 Au cours de la semaine passée: Pas du tout Un peu Assez Beaucoup 201. Avez - vous été gênée pour faire votre travail ou vos activités de tous les jours? 1 2 3 4 202. Avez -vous été gênée dans vos activités de loisirs? 1 2 3 4 203. Avez -vous eu le souffle court? 1 2 3 4 204. Avez -vous ressenti de la douleur? 1 2 3 4 205. Avez -vous eu besoin de repos? 1 2 3 4"
69,page_69,"Protocol Number: v. 3.0 Date: 11 August 2020 70 Au cours de la semaine passée: Pas du tout Un peu Assez Beaucoup 206. Avez -vous eu des difficultés pour dormir? 1 2 3 4 207. Vous êtes -vous sentie faible? 1 2 3 4 208. Avez -vous manqué d’appétit? 1 2 3 4 209. Avez -vous eu des nausées (mal au coeur)? 1 2 3 4 210. Avez -vous vomi? 1 2 3 4 211. Avez -vous été constipée? 1 2 3 4 212. Avez -vous eu de la diarrhée? 1 2 3 4 213. Etiez -vous fatiguée? 1 2 3 4 214. Des douleurs ont -elles perturbé vos activités quotidiennes? 1 2 3 4 215. Avez -vous eu des difficultés à vous concentrer sur certaines choses par exemple pour lire le journal ou regarder la télévision? 1 2 3 4 216. Vous êtes -vous sentie tendue? 1 2 3 4 217. Vous êtes -vous fait du souci? 1 2 3 4 218. Vous êtes -vous sentie irritable? 1 2 3 4 219. Vous êtes -vous sentie déprimée? 1 2 3 4 220. Avez -vous eu des difficultés pour vous souvenir de certaines choses? 1 2 3 4 221. Votre état physique ou votre traitement médical vous ont -ils gênée dans votre vie familiale ? 1 2 3 4 222. Votre état physique ou votre traitement médical vous ont -ils gênée dans vos activités sociales (par exemple, sortir avec des amis, aller au cinéma…)? 1 2 3 4 223. Votre état physique ou votre traitement médical vous ont -ils causé des problèmes financiers? 1 2 3 4"
70,page_70,"Protocol Number: v. 3.0 Date: 11 August 2020 71 Veuillez répondre en entourant le chiffre entre 1 et 7 qui s’applique le mieux à votre situation: 224. Comment évalueriez -vous votre état de santé au cours de la semaine passée? 1 2 3 4 5 6 7 Très mauvais Excellent 225. Comment évalueriez -vous l’ensemble de votre qualité de vie au cours de la semaine passée? 1 2 3 4 5 6 7 Très mauvaise Excellente © Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 EORTC QLQ -CR29 – Qualité de vie spécifique à la maladie Les patients rapportent parfois les symptômes ou problèmes suivants. Pourriez -vous indiquer, s’il vous plaît, si, durant la semaine passée, vous avez été affecté(e) par l’un de ces symptômes ou problèmes. Entourez, s’il vous plaît, le chiffre qui correspond le mieux à votre situation. Au cours de la semaine passée: Pas du tout Un peu Assez Beaucoup 226. Avez -vous fréquemment uriné dans la journée? 1 2 3 4 227. Avez -vous fréquemment uriné pendant la nuit? 1 2 3 4 228. Avez -vous eu des fuites urinaires? 1 2 3 4 229. Avez -vous eu des douleurs en urinant? 1 2 3 4 230. Avez -vous eu mal au ventre? 1 2 3 4 231. Avez -vous ressenti des douleurs au niveau de la région anale? 1 2 3 4 232. Vous êtes -vous senti(e) ballonné(e)? 1 2 3 4 233. Avez -vous vu du sang dans vos selles? 1 2 3 4 Voir page suivante S.V.P."
71,page_71,"Protocol Number: v. 3.0 Date: 11 August 2020 72 Au cours de la semaine passée: Pas du tout Un peu Assez Beaucoup 234. Avez -vous constaté des glaires dans vos selles? 1 2 3 4 235. Avez -vous eu la bouche sèche? 1 2 3 4 236. Avez -vous perdu des cheveux du fait de votre traitement? 1 2 3 4 237. Les aliments avaient -ils un goût inhabituel ? 1 2 3 4 238. Vous êtes -vous inquiété(e) de votre santé pour l’avenir? 1 2 3 4 239. Vous êtes -vous inquiété(e) de votre poids? 1 2 3 4 240. Vous êtes -vous senti(e) moins attirant(e) du fait de votre maladie ou de votre traitement ? 1 2 3 4 241. Vous êtes -vous senti(e) moins femme/homme du fait de votre maladie ou de votre traitement ? 1 2 3 4 242. Votre corps vous a -t-il déplu? 1 2 3 4 243. Avez -vous un anus artificiel (stomie)?  Oui  Non Ne répondez aux questions 49 – 55 que SI VOUS AVEZ UN ANUS ARTIFICIEL. Dans le cas contraire, passez directement à la série de questions 58 - 63. Au cours de la semaine passée: Pas du tout Un peu Assez Beaucoup 244. Avez -vous eu des fuites de gaz par votre anus artificiel (stomie)? 1 2 3 4 245. Avez -vous eu des fuites de matières fécales en dehors de votre poche de stomie? 1 2 3 4 246. La peau entourant votre anus artificiel (stomie) vous a -t-elle fait souffrir? 1 2 3 4 247. Avez -vous dû souvent changer votre poche de stomie au cours de la journée? 1 2 3 4 248. Avez -vous dû souvent changer votre poche de stomie au cours de la nuit? 1 2 3 4 249. Vous êtes -vous senti(e) gêné(e) à cause de votre poche? 1 2 3 4 250. Les soins de votre poche de stomie vous ont-ils posé des problèmes? 1 2 3 4"
72,page_72,Protocol Number: v. 3.0 Date: 11 August 2020 73 Ne répondez aux questions 56 – 61 que SI VOUS N’AVEZ PAS D’ANUS ARTIFICIEL. Au cours de la semaine passée: Pas du tout Un peu Assez Beaucoup 251. Avez -vous eu des fuites de gaz involontaires par l’anus? 1 2 3 4 252. Avez -vous eu des fuites de matières fécales par l’anus? 1 2 3 4 253. La peau entourant votre anus vous a -t-elle fait souffrir? 1 2 3 4 254. Avez -vous dû fréquemment aller à la selle au cours de la journée? 1 2 3 4 255. Avez -vous dû fréquemment aller à la selle au cours de la nuit? 1 2 3 4 256. Vous êtes -vous senti(e) gêné(e) lorsque vous alliez à la selle? 1 2 3 4 Au cours des 4 dernières semaines: Pour les HOMMES uniquement: Pas du tout Un peu Assez Beaucoup 257. Dans quelle mesure vous êtes -vous intéressé à la sexualité? 1 2 3 4 258. Avez -vous eu des difficultés à avoir une érection ou à rester en érection? 1 2 3 4 Au cours des 4 dernières semaines: Pour les FEMMES uniquement: Pas du tout Un peu Assez Beaucoup 259. Dans quelle mesure vous êtes -vous intéressée à la sexualité? 1 2 3 4 260. Avez -vous ressenti des douleurs ou une gêne lors des rapports sexuels? 1 2 3 4 © QLQ -CR29 Copyright 2006 EORTC Quality of Life Group. All rights reserved. Version 2.1 Voir page suivante S.V.P.
73,page_73,"Protocol Number: v. 3.0 Date: 11 August 2020 74 Questionnaire concernant l’expérience du patient Cher patient, Votre avis compte. Pour améliorer les soins aux patients atteints d’un cancer du côlon, nous recherchons des différentes méthodes de suivi. Par ce questionnaire nous voulons évaluer votre expérience avec ces différentes méthodes. Ce questionnaire est traité de manière anonyme. Merci pour votre participation. L’équipe de recherche de LEAD -IN FOLICOLOR Trial Question 1 Lorsque vous repensez au scanner (avec administration d’un produit de contraste par perfusion) que vous avez passé, pouvez -vous indiquer avec quelle intensité vous avez ressenti les inconvénients suivants: Encerclez le nombre qui correspond le plus à votre ressenti (une seule réponse possible): Aucun(e) Léger (légère) Modéré(e) Fort(e) Très fort(e) 11. Douleur lors de la pose de la perfusion 1 2 3 4 5 12. Sensation de chaleur, d’envie d’uriner après l’administration du produit de contraste 1 2 3 4 5 13. Sensation générale de malaise après l’administration du produit de contraste 1 2 3 4 5 14. Goût désagréable après l’administration du produit de contraste 1 2 3 4 5 15. Anxiété lors du scan 1 2 3 4 5 Voir page suivante S.V.P."
74,page_74,"Protocol Number: v. 3.0 Date: 11 August 2020 75 Aucun(e) Léger (légère) Modéré (e) Fort(e) Très fort(e) 16. Sensation de claustrophobie dans le scanner 1 2 3 4 5 17. Sentiment d’isolement, d’être seul lors du scan 1 2 3 4 5 18. Position inconfortable dans le scanner 1 2 3 4 5 19. Inconfort du fait de la durée trop longue du scan 1 2 3 4 5 20. Autre, à préciser S.V.P .: 1 2 3 4 5 …………………………………………………………………………………………………………………………………………………………… …………………………………………………………………………………………………………………………………………………………… …………………………………………………………………………………………………………………………………………………………… Question 2 Lorsque vous vous souvenez de votre expérience de la prise des deux tubes de sang supplémentaires pour cette étude en plus de votre test sanguin standard, pouvez -vous indiquer avec quelle intensité vous avez ressenti les inconvénients suivants: Encerclez le nombre qui correspond le plus à votre ressenti (une seul e réponse possible): Aucun(e) Léger (légère) Modéré (e) Fort(e) Très fort(e) 4. Aanxiété lors de la prise de sang 1 2 3 4 5 5. Douleur lors de la prise de sang 1 2 3 4 5 6. Autre, à préciser S.V.P .: 1 2 3 4 5 …………………………………………………………………………………………………………………………………………………………… …………………………………………………………………………………………………………………………………………………………… Voir page suivante S.V.P."
75,page_75,"Protocol Number: v. 3.0 Date: 11 August 2020 76 Question 3 Supposons que les méthodes de suivi reprises ci -dessous soient équivalentes et tout aussi efficaces, laquelle choisiriez -vous? Cochez la case de votre choix (une seule réponse possible).  Suivi de votre maladie sur base d’une tomodensitométrie (CT -scan) avec administration d’un produit de contraste par perfusion toutes les 8 semaines (ce qui est le traitement de référence actuel)  Suivi de votre maladie sur la base d'un prélèvement sanguin toutes les 2 semaines Question 4 Supposons que les méthodes de suivi reprises ci -dessous soient équivalentes et tout aussi efficaces, laquelle choisiriez -vous? Cochez la case de votre choix (une seule réponse possible).  Suivi de votre maladie sur base d’une tomodensitométrie (CT -scan) avec administration d’un produit de contraste par perfusion toutes les 8 semaines (cequi est le traitement de référence actuel)  Suivi de votre maladie sur la base d'un prélèvement sanguin toutes les 4 semaines Question 5 Supposons que les méthodes de suivi reprises ci -dessous soient équivalentes et tout aussi efficaces, laquelle choisiriez -vous? Cochez la case de votre choix (une seule réponse possible).  Suivi de votre maladie sur base d’une tomodensitométrie (CT -scan) avec administration d’un produit de contraste par perfusion toutes les 8 semaines (cequi est le traitement de référence actuel)  Suivi de votre maladie sur la base d' un prélèvement sanguin toutes les 8 semaines Question 6 Supposons qu'un suivi par tomodensitométrie (CT -scan) et un suivi par prélèvement sanguin soient deux méthodes de suivi équivalentes et que l’une soit aussi efficace que l’autre pour les patients atteints d’un cancer colorectal, laquelle préféreriez -vous? Cochez la case de votre choix (une seule réponse possible).  Suivi de votre maladie sur la base d’un CT -scan avec administration d’un produit de contraste par perfusion, quelle que soit la fréquence  passez à la question 7  Suivi de votre maladie sur la bas e d’un prélèvement sanguin, quelle que soit la fréquence  passez à la question 8 Voir page suivante S.V.P."
76,page_76,"Protocol Number: v. 3.0 Date: 11 August 2020 77 Question 7 Pourquoi choisissez -vous d'être suivi par tomodensitométrie (CT -scan) avec administration d’un produit de contraste par perfusion? Vous pouvez cocher plusieurs réponses.  Cette méthode me fait moins peur  Cette méthode est moins douloureuse  Je trouve cette méthode plus agréable et plus confortable  Cette méthode m’inspire plus confiance  Je devrai me rendre souvent à l'hôpital  Je devrai passer moins de temps à l'hôpital  Autre, à préciser S.V.P .: …………………………………………………………………………………………………………………………………………… …………………………………………………………………………………………………………………………… Question 8 Pourquoi choisissez -vous d’être suivi par prélèvements sanguins réguliers? Vous po uvez cocher plusieurs réponses.  Cette méthode me fait moins peur  Cette méthode est moins douloureuse  Je trouve cette méthode plus agréable et plus confortable  Cette méthode m’inspire plus confiance  Je devrai me rendre moins souvent à l'hôpital  Je devrai p asser moins de temps à l'hôpital  Autre, à préciser S.V.P .: …………………………………………………………………………………………………………………………………………… …………………………………………………………………………………………………………………………… Si vous avez des remarques, vous pouvez nous en faire part ci -dessous? …………………………………………………………………………………………………………………………………………………… …………………………………………………………………………………………………………………………………………………… …………………………………………………………………………………………………………………………………………………… ………………………………………………………………………………………………………… Merci d’avoir rempli ce questionnaire! L’équipe de recherche de LEAD -IN FOLICOLOR Trial"
77,page_77,Protocol Number: v. 3.0 Date: 11 August 2020 78 RECIST guideline ( version 1.1)
78,page_78,Protocol Number: v. 3.0 Date: 11 August 2020 79
79,page_79,Protocol Number: v. 3.0 Date: 11 August 2020 80
80,page_80,Protocol Number: v. 3.0 Date: 11 August 2020 81
81,page_81,Protocol Number: v. 3.0 Date: 11 August 2020 82
82,page_82,Protocol Number: v. 3.0 Date: 11 August 2020 83
83,page_83,Protocol Number: v. 3.0 Date: 11 August 2020 84
84,page_84,Protocol Number: v. 3.0 Date: 11 August 2020 85
85,page_85,Protocol Number: v. 3.0 Date: 11 August 2020 86
86,page_86,Protocol Number: v. 3.0 Date: 11 August 2020 87
87,page_87,Protocol Number: v. 3.0 Date: 11 August 2020 88
88,page_88,Protocol Number: v. 3.0 Date: 11 August 2020 89
89,page_89,Protocol Number: v. 3.0 Date: 11 August 2020 90
90,page_90,Protocol Number: v. 3.0 Date: 11 August 2020 91
91,page_91,Protocol Number: v. 3.0 Date: 11 August 2020 92
92,page_92,Protocol Number: v. 3.0 Date: 11 August 2020 93
93,page_93,Protocol Number: v. 3.0 Date: 11 August 2020 94
94,page_94,Protocol Number: v. 3.0 Date: 11 August 2020 95
95,page_95,Protocol Number: v. 3.0 Date: 11 August 2020 96
96,page_96,Protocol Number: v. 3.0 Date: 11 August 2020 97
